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ABSTRACT 
 
 
 The blood-brain barrier (BBB) maintains a homeostatic environment as well as 
prohibits the entrance of xenobiotics into the brain.  Because of these qualities, drug 
delivery is a fundamental challenge for the treatment of many diseases of the central 
nervous system (CNS).  Along with limiting the access of therapeutics into the brain, the 
BBB is also impaired in CNS pathologies.  Understanding the molecular cues that are 
essential for healthy BBB development and integrity may reveal targets for drug delivery 
leading to decreased progression or possible treatment of many detrimental CNS 
diseases.  While the central features of the BBB have been accepted, an innovative model 
has yet to creatively utilize this established knowledge to decipher how the unique signals 
controlling BBB properties can be optimally targeted.  To overcome these scientific 
barriers, we used zebrafish as a model organism to study BBB development in vivo.  We 
hypothesized that zebrafish could be used to genetically dissect the molecular 
mechanisms important for the development, function, and maintenance of the BBB.  The 
ultimate goal of this project was to use the zebrafish model for unbiased genetic and 
small molecule screens.  To fulfill these goals, we produced a BBB reporter line, 
Tg(glut1b:mCherry)
sj1
, to characterize the in vivo development of the BBB.  We were 
able to show through live imaging and proof-of-principle experiments, that the processes 
of CNS angiogenesis and barriergenesis occur concurrently, but do so via independent 
mechanisms.  We then initiated a forward genetic and small molecule screen with our 
BBB reporter line.  From these unbiased, high-throughput approaches, we uncovered 
several BBB mutants and chemical hits that modulate CNS angiogenesis and the glut1b 
promoter.  We also cloned one of these genetic mutants whereby the mutation was in 
gpr124, an established gene important for BBB development in mammals.  The gpr124 
mutant validates that we were able to find genetic modifiers of BBB development in our 
forward genetic screen.  The execution of these screens will not only advance our 
understanding of BBB development but potentially reveal novel genes and molecules that 
could be targeted for CNS drug delivery.  
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CHAPTER 1.    INTRODUCTION* 
 
 
Background of the Blood-Brain Barrier 
 
The blood-brain barrier (BBB) is a unique structure crucial for maintaining 
central nervous system (CNS) homeostasis.  The physical and chemical properties of 
brain endothelial cells (BECs) regulate the access of compounds from blood to brain and 
brain to blood.  While it is necessary for BECs to retain these properties, this 
physiological system hinders the efficacious delivery of therapeutics into the CNS.  Even 
though the BBB was discovered over a century ago, molecular mechanisms and 
interacting cell types necessary for BBB function and integrity have only recently 
become uncovered.  The field of BBB biology could benefit from innovatively utilizing a 
model system to dissect elements crucial for barrier properties.  These molecular 
pathways could be modulated to aid in drug delivery and prevent disease progression.  
 
 
Blood-Brain Barrier in Health and Disease 
 
 The BBB is one of three blood-CNS barriers playing a major role in CNS health 
and disease.  The BBB is endothelial cell based unlike the epithelial cell based choroid 
plexus and arachnoid barriers that exist between the cerebral spinal fluid (CSF) and 
blood
1
.  Each of these barriers exhibits a unique physical and molecular signature in order 
to protect the CNS.  While all three barriers contribute to a healthy CNS, studies on the 
BBB have been more prominent in the past few decades.  
 
A healthy neurovascular structure is necessary for neuronal function as the brain 
is a highly metabolic organ, requiring 20% of cardiac output
2
.  The BBB maintains the 
proper environment crucial for neuronal activity, ionic homeostasis, and prohibits 
harmful xenobiotics from entering the brain parenchyma
2
.  These functions provide the 
brain with a chemical safeguard and prevent neural complications.  However, it is 
unknown whether alteration of the BBB is a cause or effect of disease states.  The BBB is 
disrupted in many CNS pathologies such as Alzheimer’s disease, Parkinson’s disease, 
Multiple Sclerosis, AIDS Dementia, stroke, and epilepsy
2,3
.  Reduction in blood flow in 
the aging brain may lead to a change in cerebral protein synthesis, action potential firing, 
and electrolyte dysbalance
2
.  In a recent study by Bell et al. (2010), it was suggested that 
BBB break down exists before disease progression
4
.  Their mouse model of pericyte loss 
in the adult brain produced vascular defects and the subsequent initiation of secondary 
neurodegenerative changes
4
.  The health and function of the BBB not only plays a role in 
the pathophysiology of CNS disease, but also in the treatment of conditions such as CNS 
tumors. 
 
 
*Modified with permission.  Umans, R. A. & Taylor, M. R. Zebrafish as a model to study 
drug transporters at the blood-brain barrier. Clin Pharmacol Ther 92, 567-570, 
doi:10.1038/clpt.2012.168 (2012). 
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Drug Delivery Across the Blood-Brain Barrier 
 
The protection the BBB offers the brain simultaneously prohibits the access of 
most therapeutics from entering the CNS.  In fact, around 100% of large molecules and 
98% of small molecules are excluded from entering the brain
5
.  CNS drug penetration is 
dependent on drug lipid solubility as well as a lower molecular weight
6
.  These 
therapeutic limitations are imposed by a lack of fenestrations, presence of tight junctions, 
and expression of multi-drug resistance efflux pumps on BECs
7
.  The main multi-drug 
resistance protein found in the BBB, P-glycoprotein, was discovered due to its over-
expression in cancer cells and consequently was found to be one of the major players for 
drug resistance at the BBB
8,9
.  P-glycoprotein, as well as other members of the multi-drug 
resistance protein families, excludes various anti-cancer, anti-psychotic, anti-epileptic, 
and anti-HIV drugs
7
.  While it is necessary for the BBB to regulate the passage of 
compounds into the brain, this access is not biased towards compounds that could 
otherwise medicate CNS diseases.   
 
To more effectively deliver therapeutics into the CNS, various approaches and 
targets have been established.  Biomedical and chemical tactics are commonly employed 
to more effectively deliver drugs into the CNS.  Receptor-mediated endocytosis of 
biodegradable nanoparticles coated in various drugs successfully traverse the barrier in 
vitro and in vivo
10
.  Multi-drug resistance transporters and other endogenous mechanisms 
may be targeted for CNS drug delivery although a good structure-activity relationship is 
needed for effective drug design.  Drugs can be designed as transporter substrates or 
conversely inhibit transporters to allow more uptake of the desired therapeutic
11,12
.  Aside 
from biochemical approaches, physical techniques have also been investigated for 
opening up the BBB.  MRI- targeted ultrasound has been shown to breakdown the 
paracellular barrier between BECs in a focused area
13
.  MRI-induced BBB opening 
allowed the delivery of antibodies in the CNS yet physical damage to tissue is an artifact 
of this process
14
.  More invasive methods exist, such as intra-cerebro-infusion and 
biodegradable implants aiming to physically break down the barrier and locally deliver 
therapy
15
.  However, it is less likely patients would prefer a more crude, surgical 
technique, especially since drugs diffuse better into the blood versus the brain and 
multiple implants may need to be transplanted in order to have an effective treatment 
volume
6,16
.  Drug delivery through the olfactory system is also a route for CNS drug 
delivery.  Molecules move into the brain through the nose by entering the olfactory CSF, 
very similarly to intra-cerebro-infusions, yet less invasive
16
.  Several kinds of compounds 
such as sulfonamides, insulin, and progesterone have entered the CNS via nasal delivery 
but measures need to be taken as to not allow viruses or bacteria to enter the CNS 
through this course
11
. 
 
 
Blood-Brain Barrier Structure 
 
The BBB was first described over a century ago by Paul Ehrlich as he injected 
various water-soluble dyes into circulation and witnessed their exclusion from the brain 
and spinal cord
17,18.  Edwin Goldmann, Ehrlich’s student, further characterized these 
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observations through which he witnessed the retention of trypan blue in the CSF and not 
the periphery when injected directly into the CSF
19.  The term “blood-brain barrier” was 
however created by Max Lewandowksy whereby he discovered neurotoxic agents only 
had a harmful effect after direct injection into the brain
20
.  These pioneering experiments 
laid the ground work for the presence of a functional barrier but still posed the question 
of how and why it developed.  In fact, it wasn’t until 1969 that Brightman and Reese first 
localized tight junction proteins in between BECs, identifying the structure that was 
responsible for controlling passive diffusion of different molecules
21
.   
 
Since then, it has been widely established that the selectivity of the barrier is due 
in part to both its physical and chemical barriers
2
.  Tight junctions, proteins anchored 
between endothelial cells, are important for establishing the paracellular regulation 
between cells.  The main classes of tight junction proteins are Occludins and Claudins, 
tethered between cells by junction adhesion molecules.  When absent, loss of Claudin5 
causes a size-selective loosening of the BBB
22
.  In addition to a physical blockade, these 
proteins mediate the restriction of small molecule movement through trans-endothelial 
electrical resistance (TEER).  In fact, TEER in the periphery is reported to be fifty times 
lower than between BECs
23
.  Transporters, both carrier mediated and active efflux, 
regulate the access of particular nutrients as well as prohibit the entry of xenobiotics into 
the brain
2
.  Throughout the CNS, transporters traffic a diverse range of compounds.  
Several classes of transporters exist along blood-CNS barriers to direct the proper 
distribution of drugs, xenobiotics, and nutrients.   
 
While different transporters are isolated to specific locations among the blood-
CNS barriers, transporters of the BBB are perhaps the best characterized.  With over 40 
individual members of the ATP-binding cassette (ABC) family, ABC transporters are the 
most widely studied drug transporters at the BBB.  Of the ABC transporters, ABCB1, 
also known as Multidrug Resistance Protein 1 (MDR1) and P-glycoprotein, plays a 
prominent function in excluding compounds from the CNS.  Other ABC family members 
such as BCRP (ABCG2) and MRP4 (ABCC4) are also highly expressed at the BBB and 
play important roles in drug transport
7
.  Knockout mice of the MDR1 mouse ortholog, 
Mdr1a, revealed higher sensitivities to both neurotoxic Ivermectin and chemotherapeutic 
Vinblastine compared to wild-type littermates, indicating a protective activity of MDR1a 
at the mouse BBB
24
.  Since its discovery, many groups have attempted to modulate 
MDR1 function as a means to alter therapeutic bioavailability and to overcome multidrug 
resistance. 
 
In addition to drug efflux transporters, BECs express many anionic and carrier 
mediated systems to deliver the proper nutrition to the CNS.  Organic anion transporters 
mediate the distribution of neurotransmitter (NT) metabolites as well as other anions 
throughout the CNS
25
.  Amino acid transporters help deliver essential amino acids as well 
as regulate potential amino acid neurotoxicity in the CNS
2
.  Glucose Transporter 1 
(GLUT1), a solute carrier, is vital for proper brain function since glucose is impermeant 
to the BBB and the brain uses approximately 20% of whole-body glucose
26
.  GLUT1 is 
highly expressed in BECs in order to provide energy to the brain and is often used as a 
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marker for BBB localization and function
27
.  GLUT1 is also one of the earliest BBB 
markers as it is expressed in BECs early in brain development
28
.   
 
Furthermore, it is still widely debated in the field of brain barrier biology whether 
angiogenesis and barriergenesis occur simultaneously or in a two-step process
1
.  The first 
hypothesis suggests that barriergenesis occurs as soon as angiogenesis takes place in the 
brain.  The second hypothesis suggests that angiogenesis of leaky, immature vessels 
occurs in the brain followed later by barriergenesis whereby BECs adapt the BBB 
phenotype.  In order to advance the field of BBB biology and answer these unsettled 
mysteries about barriergenesis, innovative strategies must be applied to study BBB 
development in vivo and find novel signals controlling this process. 
 
In addition to the structural components of the BBB, different cell types associate 
with BECs to fully establish what is deemed the neurovascular unit (NVU)  
(Figure 1-1)
23
.  The NVU is a physiological arrangement of BECs, neurons, astrocytes, 
pericytes, and microglia
2
.  Pericytes, a kind of smooth muscle cell, develop during initial 
CNS angiogenesis in the rat at E12 and E11.5 in mouse before astrocytic endfeet 
ensheath BECs post-natally
27
 
29
 
1
.  Initially, astrocytes were speculated to be the cell type 
important for barriergenesis as astrocytes relay cell non-autonomous signals important for 
barrier differentiation and function
30
.  It is now understood that pericytes are important 
for barrier function in mice at a time when astrocytes have not yet developed
27
.  
Microglia, the primary immune cell of the CNS, survey their environment and change 
into phagocytic cells when activated
2
.  Many studies are now aimed at deciphering the 
molecular cues that ensue between the cell types of the NVU as a means to target them 
therapeutically.   
 
 
Molecular Mechanisms that Regulate the Blood-Brain Barrier 
 
The signals important for BBB development are still not completely understood.  
Although much remains unknown about signaling during BBB development, certain 
pathways and molecules essential for barriergenesis have recently been uncovered.  The 
cell types of the NVU relay cell-autonomous and non-autonomous signals to one another 
in order to create a functional BBB
31
 
32
 
33
 
34,35
.  Daneman et al. (2009) demonstrated that 
Wnt signaling is important for CNS angiogenesis but not peripheral angiogenesis, 
suggesting that Wnt is included in a distinct signaling profile for BBB development
36
.  G-
Coupled Protein Receptor 124 (GPR124), an orphan g-coupled protein receptor up-
regulated in colorectal cancer, is also crucial for proper BBB formation
34,35
.  
Interestingly, both Wnt and GPR124 mutant mice have similar phenotypes, including 
embryonic lethality and abnormal CNS angiogenesis in the forebrain and spinal cord
35,36
.  
Additionally, Sonic hedgehog (Shh) has been suggested to promote barrier integrity 
through secretion of Shh by astrocytes
33
.  These findings advance the understanding of 
signals important in BBB development, but do so using a candidate gene approach.  
While effective, such methods may shed bias on results, especially since some of these 
pathways are already established to be important for brain development
37,38
.   
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Figure 1-1. The neurovascular unit illustrating the various cell types of the blood-
brain barrier 
Brain endothelial cells interact with pericytes, astrocytes, neurons and microglia to 
maintain CNS homeostasis. 
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In recent years, the molecular signatures of BECs have been investigated in order 
to find specific targets at the BBB.  Daneman et al. (2010) compared the transcriptional 
profile of isolated BECs compared to vessels found in the liver and lung
39
.  From this 
study, a mouse BBB transcriptome was developed as a resource for further understanding 
what signals are enriched in this brain barrier.  Ben-Zvi et al. (2014) recapitulated a 
similar assay, isolating Mfsd2a as a BBB enriched gene
40
.  Knockout of Mfsd2a resulted 
in normal vascular patterning but a leakier BBB
40
.  Genes such as Mfsd2a and ones found 
in the mouse BBB transcriptome could ideally be targeted for CNS drug delivery. 
 
 
Models Used to Study the Blood-Brain Barrier 
 
 
Different Models to Study the Blood-Brain Barrier 
 
A variety of models are used to study BBB function and its molecular 
mechanisms.  Just as Ehrlich used several animal models to assess BBB function over a 
century ago, a current array of models exists to study BBB development and maturation.  
Among the models used are avian, rodent, insect, and tissue culture systems.  Avian 
studies first suggested there are signals in the brain milieu responsible for BBB 
development
32
.  Stewart and Wiley (1981) performed transplantation studies revealing 
peripheral vessels could adopt BBB features when they vascularized CNS transplanted 
tissue, suggesting a difference between the microenvironment of the periphery of the 
body and the brain
32
.  Rodent models, which are most popularly used, have helped 
identify the proteins important to the physical and chemical barriers of the BBB, the cell 
types that are important in the NVU, the consequences of particular cell type loss, the 
expression patterns of BBB markers, and signals that are communicated between these 
cell types
21,24,27,28,30,31,33-36,39-41
.  Armulik et al. (2010) demonstrated that pericytes in the 
rodent BBB are crucial for proper regulation by maintaining BBB function, BBB-specific 
gene expression, and astrocytic end-feet contact
41
.  This significant finding also 
contradicted previous theories that suggested that astrocytes regulate BBB formation 
even though pericytes develop before astrocytes
1,30
.  Furthermore, insect models possess 
technical advantages as they are used easily and rapidly in molecular biology
42
.  Mayer et 
al. (2009) demonstrated an evolutionary conservation of the BBB in Drosophila 
melanogaster and further demonstrated the use of fruit flies for studying BBB 
physiology
43
.  Tissue culture systems are utilized independently or in combination with 
rodent studies to examine the importance of cellular interactions and gene expression in 
the BBB
44
.  Because the various cell types of the NVU have now been established, 
models have been developed utilizing more than two cell types to more accurately 
recapitulate BBB properties in vitro.  Lippmann et al. (2011) co-cultured differentiated 
rat neural progenitor cells with rat brain microvascular endothelial cells to more 
effectively elevate and recapitulate BBB properties in endothelial cells compared to the 
more tediously acquired primary rat astrocyte cell co-culture models
45
.  It is important to 
consider the strengths and weaknesses of each of these models when asking questions 
about BBB development.  In recent years, the zebrafish (Danio rerio) has emerged as a 
suitable model organism for studying blood-CNS barriers. 
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Zebrafish as a Model Organism 
 
Zebrafish are genetically tractable vertebrates with high fecundity.  Offspring 
mature rapidly, outside of the mother, allowing for manipulation early in development.  
Within 26 hours post-fertilization (hpf), zebrafish embryos already have developing eyes, 
a brain, heartbeat and circulation.  Their transparent nature also allows for the 
visualization of these early processes in real time (Figure 1-2), making zebrafish an 
excellent model for developmental biology studies.  Zebrafish are a member of the 
teleosts, a class of fish that underwent a genome duplication event during the course of 
evolution but still have a similar number of chromosomes to humans
46
.  Due to 
conservation in genomic structure, vertebrate body plan, and systemic biology, zebrafish 
are popularly used in genetic screens to uncover genes orthologous to human
47
.   
 
Since the first small-scale mutagenesis screen in the early 1990s, zebrafish have 
been exploited for large-scale mutagenesis screens, whole-genome sequencing, positional 
cloning, insertional mutagenesis, germline transgenesis, and modeling human disease
47
.  
Forward genetic screens surged during the 1990s in Boston, Massachusetts and 
Tübingen, Germany, initially uncovering genes essential for embryogenesis
48,49
.  This 
approach identifies point mutations randomly arrayed throughout the genome based on 
phenotypic screening. Forward genetic screens have identified mutants in signaling 
pathways involved in various aspects of physiology such as vision, tumorigenesis, and 
angiogenesis
50-52
.  While it is more cost effective and easier to produce large zebrafish 
clutches for forward genetics, zebrafish are still used for reverse genetic approaches just 
as rodents are.  With the advancement of technology, reverse genetics in fish is possible 
with a variety of techniques such as morpholinos, Targeting Induced Local Lesions in 
Genomes (TILLING), Zinc finger nucleases, transcription activator-like effector 
nucleases (TALENS), and CRISPR/Cas9 systems
53-55
.  Human mutations have also been 
introduced in the zebrafish that cause the same diseases derived in human.  Mutations in 
BRAF(V600E) from human melanoma introduced into the fish also caused the disease 
and identified molecular regulators to accelerate the malignancy, suggesting a 
conservation of genes between zebrafish and mammals
56
.  Zebrafish are not only ideal for 
these genetic screens but for chemical assays as well.  
 
Chemical screens are targeted, high-throughput platforms that have been 
extensively validated with the zebrafish model system
57
.  These assays provide a 
powerful tool for therapeutic discovery as compound libraries are administered to 
multiple, whole vertebrates in a multi-well format.  The power of zebrafish genetics is 
also commonly utilized for chemical biology studies.  Chemical libraries may be applied 
to genetic mutants to rescue disease-related phenotypes as well as validate structure-
activity relationships
57
.  Previous zebrafish chemical screens have identified compounds 
that affect signaling pathways such as Bone Morphogenic Protein (BMP), cell cycle 
progression, and cancer angiogenesis
58-60
. 
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Figure 1-2. Zebrafish are a suitable model organism for studying developmental 
biological processes 
At 1 days post-fertilization (dpf), the zebrafish embryo already has a developing ear (red 
arrow), brain (black arrowhead), eye (black arrow) and beating heart (red asterisk). 
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Zebrafish as a Model to Study Blood-Brain Barrier Development 
 
Within the past decade, scientists have exploited the advantages of the zebrafish 
model system to study the BBB.  Other groups as well as our own have demonstrated the 
zebrafish BBB is comparable to that in mammals.  The zebrafish BBB possesses tight 
junctions anchored between BBB endothelium maintaining a physical barrier and 
chemical transport systems mediating active efflux and prohibiting xenobiotic entry 
61-66
.  
The tight junction protein Claudin5 is the most highly expressed homolog of the Claudin 
family in zebrafish
67
.  Knockdown of Claudin5a in zebrafish reduces ventricle lumen 
expansion but does not affect neuroepithelial tissue integrity
68
.  The zebrafish genome 
duplication event resulted in Claudin5a and Claudin5b alleles.  Each paralog’s tissue 
specificity has not been fully resolved and this may explain why Claudin5a knockdown 
may have an effect on the blood-CSF barrier and not at the BBB
67
.  Functional studies in 
zebrafish are starting to occur as Fischer et al (2013) recently demonstrated the influx of 
the substrate Rhodamine with chemical and genetic inhibition of zebrafish abcb4, what 
they deem as the zebrafish ortholog to MDR1
66
.  Further investigation of bioavailability 
of compounds at the BBB still needs to be established.  Zebrafish possess multi-drug 
resistance proteins in the gut epithelium and can actively prohibit the absorption of 
doxorubicin, a common MDR1 substrate
65
.  Because the gut lumen and BBB maintain a 
similar barrier phenotype, it is possible that Mdr1 expressed at the zebrafish BBB also 
excludes compounds similarly
69
.  All of these properties confer a functional BBB as it 
has been established in mammalian models
61
. 
 
Neural vascular biology correspondingly develops in fish as it does in mammals 
(Figure 1-3). Development of the zebrafish primordial hindbrain channels (PHBC) 
commences around 28 hpf in the zebrafish brain similarly as the formation of the 
perineural vascular plexus around E8.5 in the mouse and E11 in the rat
27,35,70
.  Growth 
factors, including vascular endothelial cell growth factor (VEGF) signaling, have been 
widely established as important and specific mitogens in vessel formation
71
.  
Heterozygous lethality of one VEGF allele demonstrates the importance of this signaling 
pathway in blood vessel development
72
.  Various zebrafish VEGF mutants also 
demonstrate genetically distinct VEGF profiles for particular blood vessel types
73
.   
 
After vasculogenesis, nascent blood vessels sprout into the developing brain 
parenchyma.  This process of newly formed vessels budding off of pre-existing ones is 
called angiogenesis
74
.  Our lab has demonstrated CNS angiogenesis occurs similarly at 
30hpf from zebrafish PHBCs as it does from the mouse perineural vascular plexus at 
E9.5-10
35,36
 (Taylor lab, data unpublished).  In the zebrafish, the main arterial route and 
vessel branching becomes hearty by 2 dpf
70
.  In addition to CNS angiogenesis, markers of 
barriergenesis also differentiate similarly in the zebrafish.  GLUT1 has been identified as 
one of the initial markers of cerebral angiogenesis in mammals appearing at E12 in rat 
and E11 in mouse BECs
28,75
.  Zebrafish also specifically express Glut1 early in 
angiogenesis suggesting that brain endothelial cells differentiate during initial CNS 
angiogenesis
64
 (Taylor lab, data unpublished).  Recently, it has been established that 
zebrafish express brain pericytes ensheathing endothelium as early as 48 hpf and  
brain development
76,77
.  The difference in timing of pericyte versus astrocyte  
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Figure 1-3. Comparative timeline of events between zebrafish and mammals 
during blood-brain barrier development 
Zebrafish vasculogenesis, CNS angiogenesis, and barriergenesis occurs similarly as it 
does in rodents.  The literature suggests that these two processes occur simultaneously, 
but a model has yet to show this in real time.  The advantages of the zebrafish model 
system could be used to more carefully dissect these processes.   
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development in the zebrafish brain may be an artifact of evolution, lack of transgenic 
lines to look at pericyte development in real time, as well as a limitation on established 
zebrafish astrocyte markers.  For example, grey matter “protoplasmic” astrocytes 
surrounding CNS blood vessels express distinctive markers from the fibrous astrocytes 
that are typically labeled with the commonly used glial fibrillary associated protein 
marker
78
.   
 
Zebrafish provide an excellent model system for identifying canonical signaling 
pathways as well as novel signals important to development.  Interestingly enough, 
expression profiles in mouse brain vasculature can be exploited in the zebrafish BBB.  
Tam et. al (2012) demonstrated the death receptors DR6 and TROY are important for 
both mouse and zebrafish barriergenesis
64
.  These death receptors were also shown to be 
regulated by Wnt signaling, suggesting conservation in BBB signaling pathways between 
mammals and zebrafish
64
.  Notch signaling has also been identified as an important 
regulator of barriergenesis in the mouse and has now been validated in the zebrafish
76,79
.  
The field of brain barrier biology could therefore benefit from further exploiting the 
zebrafish model system to uncover novel signaling pathways in high-throughput genetic 
and chemical screens. 
 
 
Hypothesis and Scope of This Dissertation 
 
The ultimate goal of this project was to use the zebrafish model for unbiased 
genetic and small molecule screens.  These in vivo strategies could uncover novel 
molecular constituents that are important in barriergenesis.  Therefore, we hypothesized 
that zebrafish can be used to genetically dissect the molecular mechanisms important for 
the development, function and maintenance of the BBB.  To test our hypothesis, we 
completed the following specific aims:  
 
1. Produce a BBB reporter line to characterize the in vivo development of the 
BBB. 
 
We hypothesize that the creation of transgenic reporter lines using genes 
important for barrier function will allow us to study the development of the BBB.  We 
first plan to create and then characterize the BBB reporter line, to survey the in vivo 
development of the BBB.  By performing proof-of-principle experiments on our 
transgenic model, we can demonstrate that this reporter is a powerful tool for studying 
BBB development in a live animal and therefore useful for high-throughput screens. 
 
2. Perform a genetic dissection of the BBB to uncover novel molecules that 
affect BBB properties. 
 
A forward genetic and chemical screen exploiting our BBB reporter line could 
uncover mutants and compounds that cause defects in CNS angiogenesis and reporter 
expression.  We will perform a small-scale F3 genetic screen after ENU treatment of 
adult BBB transgenics.  Simultaneously we will test different compound libraries in wild-
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type BBB transgenics to look for alteration in BBB structure and reporter expression.  
These approaches are not only unbiased, but present the possibility of uncovering 
unfamiliar mechanisms important in barriergenesis. The execution of this screen will not 
only advance our understanding of BBB development but potentially reveal new genes 
from cloning mutants and “hits” that could be targeted for CNS drug therapy. 
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CHAPTER 2.    GENERATION OF A BLOOD-BRAIN BARRIER REPORTER 
LINE  
 
 
Introduction 
 
 
Transgenics Used to Study the Blood-Brain Barrier 
 
Transgenic animals are modified to express non-native genetic sequences and 
have been studied to investigate developmental processes, tissues, and disease
47,80,81
.  
These models are typically constructed by placing a specific promoter sequence upstream 
of a gene that will express some bioluminescent or fluorescent protein.  However, there 
are currently no published models to study the BBB whereby a promoter localizes a 
reporter gene only to BECs.  Instead, many groups utilize endothelial cell promoters to 
study BEC development even though all blood vessels are labeled.  For example, the 
Tie2-GFP line is commonly used to study BBB development in the mouse
35,36,40
.  The 
Tie2 promoter, an endothelial specific receptor tyrosine kinase, was used to create and 
understand vascular endothelial cell growth and function 
82
.  Studies for zebrafish BBB 
development have also utilized a similar transgenic line, Tg(fli1a:EGFP)
y1 
(herein 
Tg(fli1a:EGFP)) which labels blood vessels throughout the whole organism with the 
friend leukemia virus integration 1a (fli1a) promoter driving expression of the enhanced 
green fluorescent protein (EGFP) reporter gene 
61,80,83
.  These transgenics are sufficient to 
study vessel development, but their promoter sequences are not specific to brain 
endothelium.  More recently, the Tg(l-fabp:DBP-EGFP) zebrafish reporter was generated 
to study the development and maintenance of brain barriers based on the expression and 
circulation of a 78 kDa (kilo Dalton) Vitamin-D binding protein fused to EGFP
62
.  The 
Tg(l-fabp:DBP-EGFP) line was useful for studying the functional development of the 
BBB however, this transgenic does not report on the barrier signals that are essential for 
maintaining BBB function.  If a BBB reporter line existed, studies could be performed to 
target pathways that affect molecular properties that constitute BECs versus signals that 
pertain to all endothelium.  Therefore, the field of BBB biology could benefit from the 
construction of a zebrafish BBB reporter line.   
 
 
Tol2 Transgenesis 
 
To generate tissue specific reporter lines, zebrafish labs commonly use the 
Tol2Kit.
84
  This system is ideal for transgenesis as compared to injection of regular 
plasmid Deoxyribonucleic Acid (DNA) which gives lower germline transmission rates.
84
  
Construct integration with Tol2 can also be visualized by fluorescent reporter gene 
expression.  It has been established that the Medaka fish, Oryzias latipes, possesses a 
transposable system deemed Tol2-tyr which can move in a cut and paste manner.
85
  
While zebrafish do not contain Tol2 elements, co-injection into single cell zebrafish 
embryos of a Tol2 element with Tol2 transposase transcribed in vitro results in germ-line 
integration of the Tol2 element.
86
  The Tol2Kit uses site-specific recombination-based 
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cloning that can produce a final clone containing a promoter sequence upstream of a 
reporter gene.
84
  Based on previous reports of the Tol2 system, a transgenesis rate of 50% 
is expected.
87
  Furthermore, the Tol2Kit has successfully produced transgenics such as 
those using the bactin2 and hsp70 promoters to drive GFP expression.
84
   
 
 
Materials and Methods 
 
 
Zebrafish Lines  
 
The Tg(fli1a:EGFP)
 
strain was acquired from the Zebrafish International 
Resource Center (ZIRC).  To assess glut1b expression patterns, we used two other 
transgenics, cp:EGFP, an enhancer trap line generated in our lab that expresses EGFP in 
the choroid plexus and tαc:EGFP, a transgenic line that expresses EGFP in photoreceptor 
cells and the pineal gland.  Embryos and larvae were maintained at 28.5
o
C in egg water 
(0.03% Instant Ocean).  0.003% N-Phenylthiourea (PTU) was used to inhibit melanin 
production for imaging.  Dr. Taylor injected 2 nl of 1 mg/ml bovine serum Albumin, 
Alexa Fluor 647 Conjugate (Invitrogen) into the common cardinal vein and fish were 
imaged by confocal microscopy 
 
 
Tol2 Transgenesis and Construct Microinjection 
 
The generation and injection of the BBB construct was performed in a group 
effort by multiple lab members.  To generate the construct for Tg(glut1b:mCherry)
sj1
,we 
used Gateway compatible vectors of the Tol2kit.  A 2.9 kb fragment of the zebrafish 
glut1b promoter (accession #: NM_001039808) was amplified from genomic DNA using 
a forward primer of 5’-TATTctcgagGGGGCTGATAACATTGACCT (with a Xho I 
restriction site added, lower case) and a reverse primer of 5’-
TCCAggatccCAAAAATTGTTCTTTAAAAAAAAC (with a Bam HI site added, lower 
case) and subcloned into the TOPO TA cloning vector (Invitrogen).  The glut1b promoter 
was released from the cloning vector by XhoI and BamHI double digestion and inserted 
into p5E-MCS (Tol2kit).  This 5’ entry clone was combined with middle entry clone 
pME-mCherry, the 3’ entry clone p3E-polyA, and the pDestTol2pA2 destination vector to 
create the pDest-glut1b:mCherry construct using the LR Clonase II Plus Enzyme mix 
(Invitrogen). Approximately 30 pg of plasmid DNA and 30 pg of in vitro transcribed 
Tol2 transposase messenger ribonucleic acid (mRNA) were co-injected into single-cell 
Tg(fli1a:EGFP)
 
embryos ( n= 45).  All microinjections were performed using a PV820 
Pneumatic PicoPump (WPI).  The embryos were raised to adulthood and screened for 
germline transmission by observing mCherry expression in BECs.  The 
Tg(glut1b:mCherry)
sj1
 line was bred to homozygosity and determined to contain a single 
insertion site. 
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Live Imaging Confocal Microscopy  
 
For imaging, fish (1-6 dpf) were anesthetized in 0.02% Tricaine and immobilized 
in 1.2% low melting point agarose (Invitrogen) in glass bottom culture dishes (MatTek).  
Confocal microscopy was performed on a Nikon TE2000E2 microscope equipped with a 
Nikon C1Si confocal using 488nm, 561nm and 638nm DPSS lasers for excitation. 
Images were acquired with a Nikon 20X 0.75 NA Plan Apo DIC objective and processed 
using Nikon NIS Elements software.  Confocal z stacks were acquired with a 3 micron 
step size; for time-lapse imaging, a z stack was acquired every 30 minutes for 30 hours.  
All images are 2D projections of 3D confocal z-stacks, generated using either a MIP or 
EDF algorithm.  Time-lapse movies were further processed by applying a Gaussian blur 
to the image stack before creating the 2D projection in order to remove “noise” from the 
collection of pixels. 
 
 
Adult Dissection 
 
Tg(fli1a:EGFP) and Tg(glut1b:mCherry) adults were deeply anesthetized with 
0.04% tricaine made in system water and humanely sacrificed for dissection.  Dissections 
were performed on a petri dish containing a Kim wipe soaked in 0.04 % tricaine.  Tissues 
were dissected using a razor blade and fine forceps.  Organ images were acquired on a 
Nikon SMZ 1500 stereoscope with a PRIOR Scientific Lumen 200 PRO Fluorescence 
Illumination System. 
 
 
Results and Discussion 
 
 
Selecting a BBB-Promoter, Glucose Transporter 1  
 
BECs possess chemical and physical barriers to maintain brain homeostasis.  The 
chemical barrier is mediated by transport systems, which may be metabolic, xenobiotic or 
solute specific.  Carrier-mediated efflux pumps are crucial for delivering nutrients to the 
brain that would not otherwise be accessible.  Glut1, one of these main transporters, is 
responsible for delivering glucose to the brain, as it requires 20% of whole body 
glucose
26
.  Because of this physiological need, GLUT1 is highly expressed at the 
BBB.
7,39,88
  GLUT1 is also one of the earliest markers at the BBB, and several recent 
studies have used GLUT1 expression as a functional indicator of BBB formation
36,41
.  It 
has also been reported that BBB tightness plays a pivotal role in the pattern of GLUT1 
expression during brain differentiation, demonstrating that GLUT1 serves as an indicator 
of BBB function as well as development
28,75
.  Furthermore, it has been demonstrated that 
Glut1 localizes to BECs in zebrafish
64
.  Therefore, based on its significance in BBB 
development and expression, we selected the zebrafish Glut1 homolog as a molecular 
tool for creating our BBB transgenic line.  
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To visualize in vivo development of the BBB, we created a novel transgenic 
zebrafish reporter line using the zebrafish glut1b promoter.  While zebrafish have three 
glut1 paralogs, we focused our studies on glut1b (NM_001039808), due to its 
predominant expression of mRNA in the brain
63
.  We chose mCherry for our BBB 
reporter because it matures more rapidly than other fluorescent proteins (t0.5=15 minutes) 
allowing for accurate observation of temporal expression
89
.  Injections were performed in 
the Tg(fli1a:EGFP) line so we could look for an overlap with glut1b expression in EGFP 
positive BECs (Figure 2-1).  Generating the BBB line with a transgenic labeling all 
endothelium would also allow us to study processes that affect BECs separately from the 
periphery.  We found mCherry transiently expressed in the brain vasculature of ~90% of 
injected embryos (Figure 2-2).  
 
 
Visualization of BBB in vivo Development  
 
We identified several stable transgenic lines by out-crossing transient expressers 
to Tg(fli1a:EGFP) and designated one as Tg(glut1b:mCherry)
sj1
 (herein 
Tg(glut1b:mCherry)).  To characterize the expression pattern of mCherry, we used 
confocal laser scanning microscopy on live glut1b:mCherry; fli1a:EGFP double 
transgenics.  At 6 dpf, mCherry was expressed specifically in the brain vasculature 
(Figure 2-3C) and in the myocardium (data not shown), but not in the peripheral 
vasculature (Figure 2-3F).  This expression pattern was maintained in adulthood as well 
as in the reproductive tissues of the adult (Figure 2-4).  GLUT1 is expressed in ovarian 
tissue among different species, yet there are still species specific differences in tissue 
expression patterns
90
.  When the cavities of the adults were opened, it appeared as if 
viscera like the kidney (data not shown) may also be glut1b positive which has also been 
reported in other species as glucose transport is involved in hyperglycemia and diabetes 
progression
91
.   
 
Brain vessels are very specialized so that they do not easily allow the free 
exchange of molecules into the brain.  One of these specializations includes the lack of 
fenestrations, openings in the vessel wall, a non-barrier property which is commonly seen 
in circumventricular organs
92
.  Fenestrations are not only present in these organs but have 
also been demonstrated as marker for BBB disruption
93
.  To demonstrate that mCherry 
expression was specific to endothelium that maintain BBB properties, we looked at 
mCherry in circumventricular organs in other transgenic lines.  We crossed 
Tg(glut1b:mCherry) to cp:EGFP, an enhancer trap line that expresses EGFP in the 
choroid plexus and tαc:EGFP, a transgenic line that expresses EGFP in the pineal gland.  
We found that mCherry was not expressed in the choroid plexus or pineal gland 
vasculature (Figure 2-3J and N), indicating that glut1b:mCherry in the zebrafish 
faithfully recapitulates mammalian GLUT1 expression at the BBB.   
 
Taking advantage of our in vivo model, we wanted to address a fundamental 
argument about BBB development.  Ongoing hypotheses suggest that BBB formation is 
either 1) a two-step process where CNS angiogenesis occurs and is followed by 
barriergenesis, or that 2) both CNS angiogenesis and barriergenesis occur at the same 
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Figure 2-1. Blood-brain barrier construct injection into Tg(fli1a:EGFP)
y1 
embryos 
A BBB reporter construct was engineered with the Gateway Tol2kit cloning system.  
This DNA element contained a 2.9kb fragment of the zebrafish glut1b promoter upstream 
of the mCherry reporter gene.  The DNA construct contained Tol2 sites flanking the 
transgene, so that upon co-injection with Tol2 transposase mRNA into single cell 
Tg(fli1a:EGFP) embryos, the construct would be inserted into the genome of the 
developing zebrafish.  We hypothesized that if the glut1b promoter was specific to BECs, 
we would see a yellow overlay with the red signal from glut1b and the green signal from 
fli1a.   
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Figure 2-2. Transient expression of glut1b:mCherry in fli1a:EGFP brain 
endothelium 
After co-injection of the Tol2 transposase mRNA and the glut1b construct, 
glut1b:mCherry localized to fli1a:EGFP BECs as seen here with a representative 3 dpf  
transgenic animal (anterior, right; dorsal, top).  Transient expression also reveals that the 
promoter does not localize mCherry to peripheral blood vessels.   
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Figure 2-3. glut1b is expressed in brain endothelial cells and not in 
circumventricular organs 
Upon germline transmission of the glut1b:mCherry transgene, mCherry was still 
restricted to the brain vessels of a 6 dpf animal (C) and not the peripheral vasculature (F).  
We crossed Tg(glut1b:mCherry) to two other transgenics that expressed EGFP in tissues 
that have fenestrated endothelium, the choroid plexus (H arrows and arrowhead) and 
pineal gland (L arrowhead ).  These lines were also injected with an Albumin tracer 
labeled in the far red channel to demonstrate that these BECs were functional.  As seen 
from the merge panels, glut1b is not expressed in capillaries of the choroid plexus (J) or 
pineal gland (N).   
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Figure 2-4. glut1b:mCherry is maintained in adult brain endothelial cells as well 
as reproductive tissues 
Tg(fli1a:EGFP)
 
(left tissues) and Tg(glut1b:mCherry) (right tissues) adults were 
dissected to look at glut1b expression in adulthood.   glut1b still localized to BECs in 
adulthood and was also seen in reproductive tissues like the ovaries and testes.   
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time.  The “two-step” hypothesis is largely based upon observations that immature CNS 
blood vessels are leaky to injected tracers such as Evans Blue.  However, the conclusions  
from these studies have been challenged due to the methodology used
1
.  While growing 
evidence indicates that barriergenesis and CNS angiogenesis may be linked, the inability 
to visualize these processes in real time limits the observation of the earliest steps of CNS 
vascular development
36
.  To address this issue, we performed time-lapse confocal 
microscopy to examine the temporal induction of barrier properties.  In zebrafish, CNS 
angiogenesis begins in the hindbrain at approximately 30 hpf when endothelial tip cells 
originating from the PHBCs migrate into the brain parenchyma
70
.  These vessels 
eventually form the central arteries (CtAs) that interconnect the PHBCs with the basilar 
artery.  Using live glut1b:mCherry; fli1a:EGFP double transgenics, we imaged 
angiogenesis and barriergenesis from 30 to 60 hpf.  We observed that endothelial cells 
express mCherry immediately upon entering the brain (Figure 2-5), indicating direct 
evidence for the hypothesis that barriergenesis and angiogenesis occur simultaneously. 
 
 
Conclusion 
 
A comprehensive understanding of the development and maintenance of the BBB 
has been hampered by difficulties in observing the BBB in vivo.  To do this, we generated 
a transgenic zebrafish line, Tg(glut1b:mCherry)
sj1
, to serve as an in vivo reporter of the 
BBB.  These animals were used for imaging live BBB formation, a process that has not 
been able to be performed until now.  We show that our transgenic line drives expression 
just like the mammalian GLUT1 ortholog, specifically in BECs and not in the vasculature 
of peripheral tissues or circumventricular organs with fenestrated capillaries.  This 
expression pattern is maintained until adulthood as well.  Furthermore, we show evidence 
for the first time that the processes of barriergenesis and angiogenesis happen 
concurrently in a live animal.  
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Figure 2-5. Angiogenesis and barriergenesis occur simultaneously 
Stills were taken from a live time-lapse movie of glut1b:mCherry development.  As soon 
as fli1a:EGFP positive tip cells migrated into the zebrafish brain parenchyma at 30 hpf, 
the endothelium turned positive for glut1b:mCherry expression.  This expression is 
visualized over the 30 hour movie. 
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CHAPTER 3.    CHARACTERIZATION OF THE BLOOD-BRAIN BARRIER 
REPORTER LINE*  
 
 
Introduction 
 
 
Characteristic Properties of the BBB 
 
The BBB is well-known for restricting xenobiotic entry into the CNS while still 
providing the proper nutrition for brain tissue.  Since the start of the 20
th
 century, the 
BBB has been known to maintain a functional partition between the circulatory system 
and the CNS
17-19
.  It was not until quite some time later, that seminal transplant studies 
elucidated the importance of the brain milieu for a functional barrier
32
.  Electron 
microscopy later revealed that tight junction proteins in between brain endothelium 
regulate the passive transport of substances into the brain tissue
21
.  Multi-drug resistant 
proteins found up-regulated in cancerous tissues were also found localized to BECs as a 
mechanism to explain poor drug penetration in the brain
8
.  Localization of transport 
systems in the BBB was also congruent with the highly metabolic nature of the brain
28,75
.  
Together, these specific proteins located along the brain endothelium are what give the 
BBB its special properties and function.   
 
 
Methods for Testing the Function and Structure of the BBB 
 
 
Functional Protein Markers. The features responsible for creating the physical 
and chemical barriers in the CNS have been widely established and are used as traditional 
markers of BBB integrity.  In addition to studying the normal protein expression of each 
of these markers, multiple knock-out animals have been generated to assess their 
biological contributions to CNS barriers
22,24,94,95
.  Tight junction proteins anchored 
between BECs are responsible for regulating the free exchange of factors that circulate 
between the blood and the CNS.  Tight junctions compose an intricate network to tether 
brain endothelium and are vulnerable to destruction in various disease states
2
.  In fact, 
each Claudin family member regulates the access of different sized molecules
2,22
.  
Claudins are expressed early in zebrafish development and lack of functional Claudin 
affects the blood-CSF barrier
62,67
.  The ABC transporter family proteins, BCRP and 
MDR1 are two of the most widely studied features in the chemical barrier that maintain 
drug distribution throughout the BBB
7
.  While these proteins have been thoroughly 
established in the mammalian BBB, recent zebrafish work has demonstrated the presence 
of multi-drug resistance proteins in fish as well
65,66,96
.  Studies have also used the  
 
 
*Modified with permission.  Umans, R. A. & Taylor, M. R. Zebrafish as a model to study 
drug transporters at the blood-brain barrier. Clin Pharmacol Ther 92, 567-570, 
doi:10.1038/clpt.2012.168 (2012). 
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expression of carrier-mediated transporters like GLUT1 to demonstrate functional 
integrity of the BBB
27,75
.  In fact, GLUT1 haploinsufficiency results in high brain  
dysfunction and elucidates the importance of this transport system in the CNS
2
. 
 
 
Tracer Injections. Erhlich’s tracer injections between brain and the CSF were 
what initially identified a barrier between the blood and CNS
17,18
.  Additional trypan blue 
injections performed by his graduate student in the early 20th century helped further 
establish the functional compartment between the blood and CSF
19
.  Injections with 
trypan and Evans blue are not antiquated and still typically performed to assess the 
development of the BBB and its function in disease states
27,97
.  However, caution should 
be taken when assessing these results as large injection volumes may cause staining of 
the brain in instances smaller volumes would not
1
.  With the advancement in imaging 
techniques, fluorescence microscopy is also commonly used to look at the integrity of the 
BBB.  Functional studies have utilized circulating proteins or tracers conjugated to 
fluorescent dextrans to visualize BBB function which is ideal in the optically transparent 
zebrafish system
35,40,61
.   
 
 
Materials and Methods 
 
 
Immunohistochemistry (IHC) 
 
These experiments were performed in conjunction with the other graduate 
research assistant, Dr. Hannah Henson.  For tissue sectioning, embryos were fixed in 4% 
paraformaldehyde overnight at 4ºC, washed in 1x Phosphate Buffered Saline (PBS), and 
stored in 30% sucrose at 4ºC.  Embryos were embedded in OCT and stored at -20 ºC.  
Tissue sectioning was performed using a Leica CM 1950 cryostat.  Transverse sections 
were done on 30hpf and 36hpf embryos and coronal sections were done on 48hpf-6dpf 
embryos.   
 
For Glut1 and Mdr1 immunohistochemistry, primary antibodies included rabbit 
anti-Glut1 (1:200; Novus Biologicals) mouse anti-GFP (1:500; Invitrogen), mouse anti- 
Mdr1 (1:20, Calbiochem), and rabbit anti-GFP (1:500, Invitrogen).  Secondary antibodies 
included goat anti-rabbit 555 (1:400; Invitrogen), goat anti-mouse 488 (1:1000; 
Invitrogen), goat anti-mouse 555 (1:200, Invitrogen), and goat anti-rabbit 488 (1:200, 
Invitrogen).  Antibody dilutions were prepared in 1xPBS/Triton 0.03% (PBST).  Sections 
were washed in 1x PBS for 5 minutes and in PBST 3 times for 5 minutes.  Blocking was 
done in 5% goat serum and incubated for 3 hours at room temperature.  Primary 
antibodies were added overnight at 4ºC. Secondary antibodies were added for 2 hours at 
room temperature.  Washes in PBST were performed after primary and secondary 
antibody incubations.  Sections were DAPI stained, rinsed briefly in 1x PBS, and 
mounted with Fluoromount (Electron Microscopy Sciences) before adding the coverslip.  
All images were taken on a Nikon AZ100 microscope using NIS-Elements AR 3.2 
software.   
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Live Imaging Confocal Microscopy 
 
For imaging, fish (1-6 dpf) were anesthetized in 0.02% Tricaine and immobilized  
in 1.2% low melting point agarose (Invitrogen) in glass bottom culture dishes (MatTek).  
Confocal microscopy was performed on a Nikon TE2000E2 microscope equipped with a 
Nikon C1Si confocal using 488nm, 561nm and 638nm DPSS lasers for excitation.  
Images were acquired with a Nikon 20X 0.75 NA Plan Apo DIC objective and processed 
using Nikon NIS Elements software. Confocal z stacks were acquired with a 3 micron 
step size.  All images are 2D projections of 3D confocal z-stacks, generated using either a 
MIP or EDF algorithm.  Time-lapse movies were further processed by Dr. Jennifer Peters 
by applying a Gaussian blur to the image stack before creating the 2D projection. 
 
 
Transgenic Wnt Inhibition by Induction of Axin-1  
 
Embryos from a Tg(glut1b:mCherry;fli1a:EGFP) female crossed to a Tg(hsp70l-
1:GFP-Axin1)
zd13
  (herein Tg( hsp70l-1:GFP-axin1)) male were transferred into a 1.5 ml 
centrifuge tube with 0.5 ml egg water/PTU and placed in a heating block set to 38
o
C.  
Heat shock was performed at 24 hpf and 48 hpf for either 30 min or 60 min each.  
Tg(glut1b:mCherry)
 
embryos express mCherry in early development due to maternal 
deposits that obscure mCherry expression in BECs up to 3 dpf.  Thus, the effects of heat 
shock-induced Axin1 could not be easily visualized prior to 3 dpf.  Therefore, a second 
heat shock at 48 hpf was necessary to maintain sufficient levels of Axin1 for imaging at 
78 hpf. 
 
 
Small Molecule Treatment with VEGFR Inhibitors  
 
These experiments were performed by Dr. Michael Taylor.  For drug treatments, 
AV-951 (Selleckchem), DMH1 (Tocris), DMH4 (Sigma), and Cyclopamine (Sigma) 
were prepared as stocks in 100% DMSO at 10 mM and applied to 24 hpf embryos at a 
final concentration of 1 µM, 10 µM, 10 µM, and 50 µM, , respectively. 
 
 
Troponin (tnnt2a) Morpholino 
 
We generated a tnnt2a morpholino (Gene Tools) using the previously published 
morpholino sequence
98
. A 2 mM stock of morpholino was prepared upon receiving the 
lyophilized powder from Gene Tools.  The stock was heated up at 55 °C for 5 minutes, 
allowed to cool down, and then prepared with 1% phenol red for injection.  
Approximately 4 ng of tnnt2a morpholino was injected into single-cell embryos from a 
Tg(glut1b:mCherry)
sj1
; Tg(fli1a:EGFP)
y1
 male X TL female cross, resulting in >90% of 
embryos with no heartbeat.  Embryos were imaged at 2 dpf.   
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Albumin Alexa Fluor 647 Injection 
 
For tracer microinjection, Dr.  Michael Taylor injected 2 nl of 1 mg/ml bovine 
serum albumin, Alexa Fluor 647 Conjugate (Invitrogen) into the common cardinal vein 
and imaged by confocal microscopy.  All microinjections were performed using a PV820 
Pneumatic PicoPump (WPI).  Injection volumes were calculated using a 0.01 mm Stage 
Micrometer (Fisher Scientific). 
 
 
Results and Discussion 
 
 
Characterization of Zebrafish BBB Development 
 
After we achieved stable germline transmission with Tg(glut1b:mCherry), 
animals were mated to homozygosity. Our next goal was to perform proof-of-principle 
experiments to demonstrate the usefulness of our BBB reporter and that the BBB is 
comparable in fish and in mammals.  To do so, we performed experiments to take 
advantage of the zebrafish’s transparency, genetic tractability and ease in chemical 
treatment. 
 
 
IHC with BBB Markers. We examined the zebrafish brain microvasculature for 
the presence of endothelial tight junctions and the expression of transporters localized to 
BECs. We found that zebrafish BECs express the tight junction protein Claudin 5 and the 
transporter Glut1 as early as 2 dpf, consistent with previous studies (Figure 3-1)
62,64
.  
Furthermore, we demonstrated for the first time that zebrafish BECs express the drug 
efflux transporter, Mdr1 throughout development (Figure 3-2)
65
.  Together, these 
observations indicate that the zebrafish expresses BBB markers as do mammals. 
 
 
Function of Newly Formed Vessels. We next examined the integrity of newly 
formed brain vessels since zebrafish are amenable to early embryonic visualization.  We 
injected Albumin, Alexa Fluor 647 conjugate as a semi-endogenous permeability tracer 
into the cardinal vein of Tg(glut1b:mCherry; fli1a:EGFP) double transgenics prior to 
CNS angiogenesis and imaged from 30 to 60 hpf.  We found that albumin was contained 
within the lumen of the vasculature as new vessels migrated into the brain parenchyma 
(Figure 3-3).  These results show that physical barrier properties are present even at the 
earliest stages of brain vascular development, a hypothesis that is widely debated
1
.  
However, during this time course, some albumin appeared to enter the brain ventricles 
(Figure 3-3 asterisks).  This ventricular “leakage” is likely due to the lack of a functional 
choroid plexus, which develops at 4 dpf in zebrafish and is consistent with the lack of 
barrier properties in the choroid plexus vasculature at later developmental stages
99,100
. 
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Figure 3-1. Zebrafish brain endothelial cells express Claudin5 and Glut1 during 
development 
Tg(fli1a:EGFP) animals were sectioned to look at the co-localization of BBB markers to 
EGFP positive blood vessels.  Just as the mammalian BBB, embryonic, larval, and adult 
zebrafish express tight junction proteins like Claudin5 (A) and efflux transporters like 
Glut1 (B) in BECs.   
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Figure 3-2. Zebrafish brain endothelial cells express Mdr1 during development 
Tg(fli1a:EGFP) animals were sectioned to look at the co-localization of Mdr1 to EGFP 
positive blood vessels.  Sections reveal that zebrafish express one of the main BBB 
transports, Mdr1, in BECs over the course of development.  
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Figure 3-3. Newly formed vessels are impermeable to albumin 
Tg(glut1b:mCherry;fli1a:EGFP) embryos were injected with Albumin conjugated to an 
Alexa Fluor 647 prior to CNS angiogenesis and visualized with live confocal imaging 
microscopy.  These stills from the movie reveal that nascent glut1b positive blood vessels 
retain the large tracer when they migrate into the brain unlike the blood-CSF barrier 
(asterisks).  
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Signals that Regulate Barriergenesis 
 
 
Wnt Signaling. Wnt is a classical signaling pathway important for the initial 
stages of embryonic development but has also underlies the role in the health and 
differentiation of blood vessel morphogenesis 
101
.  Recent studies in mice have shown 
that canonical Wnt/β-catenin signaling plays a critical role specifically in CNS 
angiogenesis and BBB development
36,102
.  However, the onset of barriergenesis is 
difficult to resolve in these models due to embryonic lethality, the lack of normal CNS 
blood vessels, and the inability to visualize development in vivo.  Therefore, to examine 
the effects of Wnt signaling on barrier formation in zebrafish, we crossed 
Tg(glut1b:mCherry; fli1a:EGFP) to Tg( hsp70l-1:GFP-axin1), a transgenic line that 
allows for heat shock-dependent expression of Axin1, a potent inhibitor of Wnt 
signaling
103
.  Modulation of heat shock parameters allowed for temporal and graded 
induction of Wnt inhibition.  We performed heat shock for 60 minutes on the triple 
transgenic embryos and examined the effects at 3 dpf.  While heat shock had no effect on 
control embryos without the axin-1 transgene (Figure 3-4C), we found that induction of 
Axin1 for 60 minutes completely inhibited angiogenesis and resulted in displaced 
mCherry expression (Figure 3-4G).  These results are consistent with studies using 
conditional mouse knockouts of Wnt signaling, where Glut1 is ectopically expressed
36
.   
 
To determine if we could dissect the contribution of Wnt signaling to both 
angiogenesis and barriergenesis, we reduced the duration of heat shock to 30 and 15 
minutes.  While 15 minute heat shock had no obvious effect (data not shown), we found 
that 30 minute heat shock was permissive for angiogenesis, but significantly inhibited 
mCherry expression (Figure 3-4K).  These data indicate that there may be a Wnt 
signaling gradient that differs between angiogenesis and barriergenesis and that the level 
of inhibition may reflect differences in the expression of specific Wnt target genes.  
Differences in expression may explain why a canonical pathway has such a tissue 
specific phenotype.  This interpretation of our results is also consistent with previous 
work demonstrating that specific Wnt ligands are spatiotemporally expressed throughout 
the developing mammalian brain and variably affect barriergenesis
36
.   
 
 
VEGF, Shh, and BMP Signaling. As an additional proof-of-principle, we 
wanted to look further into signaling pathways important for mammalian barriergenesis 
in our zebrafish BBB model.  With live imaging, we witnessed that barrier properties 
were present as soon as BECs migrated into brain tissue.  Furthermore, we hypothesized 
that if CNS angiogenesis and barriergenesis were linked, then barrier properties should 
not be inducible in the absence of angiogenesis.  This idea is commonly seen in BBB 
rodent studies, where knocking out genes important for barrier properties simultaneously 
disrupts CNS angiogenesis
35,36
 .  To test this interpretation, we chemically inhibited 
angiogenesis after the initial stages of development but before CNS angiogenesis 
occurred.  At 24 hpf, we added the potent VEGF Receptor antagonists AV-951 
(Tivozanib) and DMH4
 
to our BBB transgenic line and imaged the embryos after a 24  
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Figure 3-4. Levels of Wnt inhibition are permissive for angiogenesis but not 
barriergenesis 
Transgenic hsp70I-1:GFP-axin1;glut1b:mCherry;fli1a:EGFP or 
glut1b:mCherry;fli1a:EGFP control embryos underwent heat shock at 24hpf at 38°C to 
deduce whether Wnt signaling was required for barrier properties in the developing 
zebrafish BBB.  As seen in mice, 60 minute heat shock obliterated CNS angiogenesis and 
therefore barrier properties in the zebrafish BBB (G).  However, titrating Axin-1 
induction back to a 30 minute heat shock allowed CNS angiogenesis to occur without 
barrier properties (K), suggesting that Wnt signaling is required for the initiation of 
barrier formation but not CNS angiogenesis.  
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hour exposure
104,105
.  As expected, both compounds completely inhibited CNS 
angiogenesis (Figure 3-5).  Surprisingly, the PHBCs, where hindbrain angiogenesis 
originates, strongly expressed mCherry, indicating that Glut1 can be induced in CNS 
vessels in the absence of angiogenesis (Figure 3-5).  In contrast, previous work showed 
that Wnt signaling was necessary for GLUT1 expression in the perineural vascular plexus 
in the absence of CNS angiogenesis, thus implicating Wnt signaling in both angiogenesis 
and barriergenesis
31
.  However, our data indicate that the acquisition of barrier properties, 
while dependent on Wnt signaling, is a distinct process from CNS angiogenesis and 
independent of VEGF signaling. 
 
We next examined the role of Shh and BMP signaling on barriergenesis, because 
both pathways are known to be involved in vascular development
106
.  In fact, a recent 
report demonstrated that brain astrocytes secrete Shh, BECs express Shh receptors, and 
concluded that the Shh pathway promotes BBB formation during embryonic development 
and adulthood
33
.  To test this finding in zebrafish, we added the Shh pathway antagonists 
Cyclopamine to our transgenic line and found no obvious defects in either angiogenesis 
or barriergenesis (Figure 3-6G).  We also found no effects with the BMP pathway 
antagonist DMH1 (Figure 3-6K).  Thus, our results indicate that Shh and BMP signaling 
are not required for the initial induction of barrier properties in zebrafish. 
 
 
Circulation and Glut1 Expression. We also wanted to determine if vascular 
circulation influenced the relationship between angiogenesis and barriergenesis.  Recent 
studies have shown that shear stress plays a key role in the expression of important 
transporters and paracellular protein complexes that cause BEC differentiation 
107
.  
Because zebrafish can survive early development in the absence of circulatory flow, we 
injected our BBB reporter line with a morpholino antisense oligonucleotide that targets 
cardiac troponin T2A (tnnt2a) mRNA
98
.  Embryos deficient for tnnt2a have a 
nonfunctional heart but little effect on CNS angiogenesis even without circulatory 
flow
108
.  Similarly, we found that tnnt2a morphants had thinner vessel lumens, most 
likely due to the lack of pressure from circulatory flow.  However, we unexpectedly 
found that the tnnt2a morphants developed a CNS vasculature that still strongly 
expressed mCherry, suggesting that circulation may not be essential for barriergenesis 
(Figure 3-7).  Because the vessel lumens were most likely collapsed, it is hard to 
determine quantitatively if tnnt2a morphants had an actual increase in glut1b expression 
as the mCherry signal may just be more concentrated due to the change in vessel 
structure (Figure 3-7H).  If glut1b expression was actually increased, we suspect that 
hypoxia due to the loss of circulation might induce Glut1 overexpression at the BBB and 
therefore be relevant in neurological diseases such as stroke. 
 
 
Conclusion 
 
In conclusion, we report the first direct observation that BBB formation is 
initiated at the same time as CNS angiogenesis.  Using time-lapse confocal microscopy, 
we showed that barriergenesis (i.e. the initiation of BBB development) occurs 
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Figure 3-5. Angiogenesis is not required for barriergenesis to occur 
VEGFR-2 antagonists 1 µM AV-951 and 10 µM DMH4 were added to 24hpf embryos 
before barriergenesis.  As expected, both inhibitors prevented CNS angiogenesis but to 
our surprise, glut1b expression still persisted (G, K).   
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Figure 3-6. Shh and BMP signaling is not required for glut1b expression in the 
zebrafish blood-brain barrier   
50 µM Cyclopamine and 10 µM DMH1 were added to 24 hpf 
Tg(glut1b:mCherry;fli1a:EGFP) to assess the effects of Shh and BMP signaling on 
barrier properties.  Neither Cyclopamine (G) nor DMH1 (K) caused any effects on 
barriergenesis.   
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Figure 3-7. Circulation is not required for glut1b expression in the zebrafish 
blood-brain barrier 
Single cell Tg (glut1b:mCherry;fli1a:EGFP) embryos were injected with the tnnt2a 
morpholino to assess the effects of shear stress on barrier properties.  While heartbeat and 
circulation were obsolete, morphants still exhibited glut1b expression (E).  Morphant 
vessels appeared brighter (E) compared to un-injected control siblings (A) but morphant 
vessels also appeared collapsed (H) compared to control vessels (D).   
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immediately as new vessels sprout into the brain parenchyma and that these nascent 
blood vessels are functional.  This is a novel finding that gives support for one of the two 
competing hypothesis in the field of BBB development.  This result was possible with the 
advantages of our zebrafish model organism.  Furthermore, using a combination of 
genetic and chemical approaches, we demonstrate that angiogenesis and barriergenesis, 
while occurring simultaneously, use different signaling mechanisms.  We demonstrated 
that complete inhibition of canonical Wnt signaling blocks CNS angiogenesis, and that 
partial inhibition of Wnt signaling permits CNS angiogenesis but prohibits barriergenesis.   
 
We expected Wnt signaling modulation to have an effect on mCherry expression 
since it has been shown that Glut1 expression is downstream of Wnt signaling.
31,36,64
 
Additionally, we show that VEGFR antagonists block CNS angiogenesis, but do not 
prevent the induction of barrier properties in established blood vessels, indicating that 
barriergenesis is independent of VEGF signaling.  Ultimately, these results show that 
CNS angiogenesis and barriergenesis occur simultaneously, but require distinct signals 
for proper formation.  Our in vivo model provides a valuable tool for dissecting the 
complexities of the BBB that may ultimately lead to new treatment options for a variety 
of CNS diseases.  
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CHAPTER 4.    A FORWARD GENETIC SCREEN TO UNCOVER BLOOD-
BRAIN BARRIER MUTANTS  
 
 
Introduction 
 
 
Genetic Screen Strategies 
 
Genetic screening methods have been successful at dissecting signals important 
for developmental processes as well as their unknown functions.  In molecular biology, 
there are two kinds of genetic screens that can be utilized, reverse and forward.  In 
reverse genetic screens, a gene of interest is targeted to be deleted or knocked down and 
the phenotypic effects of this genetic ablation are observed.  Common reverse genetic 
techniques include antisense oligonucleotide morpholinos, TILLING, retroviral-mediated 
mutagenesis, zinc finger nucleases, conditional bipartite systems for knocking out genes 
through transgenesis, TALENS, and the CRISPR/Cas9 system
53-55
.  Forward genetics 
takes the opposite approach from reverse genetics.  In a forward genetic screen, random 
point mutations are created in a founder generation, passed on to successive offspring, 
and mutations are discovered based on phenotypes that are identified.  Forward genetic 
screens usually identify recessive mutations in a F3 generation, but haploid animals can 
be screened at an F2 generation to expedite screening for mutant phenotypes
109,110
.  
Therefore it is important to note the different starting and end results in these two kinds 
of assays.  Reverse genetics is useful for screening for phenotypes if there is a gene of 
interest to be studied.  Forward genetics proves to be a very useful and an unbiased 
strategy at identifying previously unknown pathways important for physiological 
processes.  
 
 
Significance of Forward Genetic Screens  
 
The first forward genetic screens were carried out in micro-organisms and helped 
identify the importance between genes and enzymes, gene structure, and even the genetic 
code
53
.  Non-vertebrates such as the nematode (Caenorhabditis elegans) and fruit fly 
(Drosophila melanogaster) have also been used in forward genetics, elucidating loci 
involved in programmed cell death and cell polarity
111,112
.  These findings were 
extremely significant to the field of biology and this research contributed to Nobel Prize 
awards in Medicine and Physiology.  Important pathways that are conserved among 
various species have been identified in these model organisms, but their simplistic 
morphology limits what biological structures can be observed in these screens.   
 
 
Zebrafish and Forward Genetic Screens 
 
The zebrafish proved to be a useful vertebrate for forward genetics.  It is possible 
to perform forward genetic assays in murine models, but intrauterine development, cost, 
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and limiting size for pup liters make it difficult to study developmental processes in 
mammals
109
.  Because forward genetics is a high-throughput screening strategy, the 
fecundity of adults and transparent and rapid development of the embryo made zebrafish 
a suitable organism for the first genetic screens initiated by Streisinger and colleagues in 
the 1980s
113,114
.  These original zebrafish screens utilized gamma-ray irradiation until 
chemical mutagens were preferred in subsequent large-scale screens because of their 
ability to effectively generate germ-line mutations in a variety of loci
48,49
.  The two first 
large-scale genetic screens in zebrafish in Boston and Tübingen identified over 6,000 
mutant phenotypes, one third of these mutants being in developmental processes
53
.  Since 
then, genes not only involved in embryogenesis but also in vision, cancer, the 
cardiovascular system, and brain development have been identified as well
50,51,115-117
. 
 
 
Treatment and Breeding Scheme in Zebrafish Forward Genetic Screens 
 
Typical forward genetic screens in zebrafish utilize breeding schemes for 
identification of homozygous recessive mutations that are inherited in a Mendelian 
manner in F3 diploid embryos (Figure 4-1).  With this approach, founder males are 
treated with a chemical teratogen to introduce point mutations into their genome.  N-
ethyl-N-nitrosourea (ENU), one of the most common chemical mutagens, is an alkylating 
agent that introduces random point mutations at loci throughout an organism
118
.  The 
transfer of the ethyl group from ENU onto oxygen or nitrogen causes mis-pairing during 
DNA replication and after two rounds, causes a single base pair substitution and 
mutation
119
.   
 
The regimen and concentration of ENU used to treat zebrafish has been 
thoroughly studied, looking at survival rate, fertility, and frequency of mutation
120,121
.  
Efficiency of ENU mutagenesis is typically identified by a specific locus test, whereby 
ENU treated males are crossed to fish that are heterozygous for a known recessive 
mutation and their subsequent progeny are screened for the known mutant phenotype.  
Because ENU affects all of the cells in the adult male, only mutations generated in the 
pre-meiotic sperm cells passed onto non-mosaic F1 progeny will be identified in further 
generations
121
.  After treated founder males recover, they are bred to wild-type females to 
produce a F1 generation.  The initial genetic screens reported that every F1 individual 
possessed a genetic lesion that affected embryonic development.
48,49,53
  F1 progeny are 
then outcrossed to a polymorphic strain for future genetic cloning or in-crossed to other 
F1 progeny to create the F2 generation.  Crossing F1 progeny together will increase the 
number of screened genomes.  After F2 families have been generated and raised to 
adulthood, pairs within F2 families are mated to identify the non-mosaic, recessive 
mutations in F3 offspring based on phenotypic inspection.  The chance of finding a 
mutation in a particular mutagenized genome is determined by the number of crosses set 
up for that family.  The probability of successfully finding a mutation in one family is 
shown in Equation 4-1 where n is the number of successful matings between pairs of a 
given family
48
.   
 
 P = (1-0.75
n
) (Eq. 4-1) 
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Figure 4-1. Breeding scheme for a zebrafish F3 forward genetic screen 
Founder males are treated with ENU and out-crossed to wild-type females.  The F1 
generation is produced and offspring are heterozygous for germline mutations.  In-crosses 
in the F1 or outcrossing F1 hets to wild-type fish will create F2 families.  50% of the fish 
within a F2 family are heterozygous for mutations from their F1 parents.  F2 fish are 
crossed to one another to generate F3 progeny.  F3 offspring will be screened for recessive 
mutations inherited in a Mendelian manner.  Therefore, if a F3 clutch carries a recessive 
mutation, 25% of that clutch will present a phenotype.   
 
 
 
 
 
 
  40 
For example, if each family is mated to one another six times (n = 6), the 
probability of finding a mutation in that family will be P = (1-0.75
6
), where P = 0.82 or 
82% whereby only 18% of mutations for that family are lost.
48
  Rates of mutation after 
ENU treatment have been identified as 1.7 embryonic lethal mutation per single 
mutagenized genome
120
.   
 
 
Materials and Methods 
 
 
ENU Treatment Materials 
 
For each isopack of ENU, a particular amount of solutions were prepared in a 
fume hood each week of treatment.  The fume hood was covered in spill pads and the 
sash was concealed in aluminum foil to maintain a dark environment for the treated fish.  
100 ml of 10 mM NaPO4 buffer (pH 6.5), 1 L of ENU treatment water without tricaine (1 
mM NaPO4 (pH 6.5) made in fish system water), 3 L 1 mM NaPO4 buffer with tricaine 
for every tank of fish to be treated, 1 mL of 10 mM NaPO4 buffer (made in egg water) for 
spectrophotometric readings, two cuvettes, 5 L of inactivating solution (containing 20% 
Na2S2O3, 1% NaOH), and stock tricaine at 0.4% were prepared every week.  Four larger 
mating tanks were used for treatment on each set of fish; one tank with an insert and the 
three others without.  Two luer tip syringes and 50 mL conical tubes were needed for 
preparation of the ENU isopack  
 
 
ENU Preparation and Handling 
 
After the treatment solutions were prepared, a luer tip syringe was used to add 10 
mM NaPO4 buffer to the ENU isopack.  A second syringe (with tip attached) was used for 
pressure buildup in the isopack because of the displaced gas that was produced as the 
buffer was added to the container.  60 mL of 10mM NaPO4 buffer was first added 
followed by another 25 mL to total 85 mL of 10 mM NaPO4 buffer in an isopack.  20 mL 
of air was then carefully removed followed by 20 mL of ENU stock solution.  This 20 
mL aliquot was placed into a 50 mL conical tube and repeated so that each of the two 
conical tubes would have around 40 mL total between the two.  ENU was mixed by 
pouring the tubes back and forth.  To inactive any hazardous ENU spills and for clean-up, 
5 L of inactivating solution containing 20% Na2S203 and 1% NaOH was prepared.   
 
 
ENU Spectrophotometry Readings 
 
Because each isopack of ENU varied between bottles, the final concentration of 
ENU was calculated based on its optical density (OD) value with a spectrophotometer.  
Based on previously published screens, 3 mM ENU was the desired concentration for 
each treatment
120.  ENU’s molecular weight is 117.11 grams per mole and at a desired 
molarity of 3 mM that would constitute 0.351mg/ml of ENU.  For 1 mg/ml of ENU, at a 
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spectrophotometer reading of 398 nm, the OD is 0.72
122
.  ENU was diluted 1:20 before 
being placed in a cuvette for readings on the spectrophotometer.  Therefore, the dilution 
factor in 1000 ml treatment water to total to 3 mM per ENU isopack was calculated as 
shown in Equation 4-2.   
 
 [O.D.398 value] X 20 (dilution factor)  (Eq. 4-2) 
[0.72] X [0.351 mg/ml] 
 
1000 mL was divided by this dilution factor to decide what volume of ENU stock was 
needed to get a desired final concentration of 3 mM ENU.   
 
 
ENU Treatment Paradigm and Fish Care 
 
ENU treatment was performed on 23 wild-type homozygous Tg(glut1b:mCherry 
;fli1a:EGPF) adult males with positive spawning and fertility histories.  Eleven males 
and twelve males were separated in two initial treatment tanks, respectively, containing 
an insert and regular system water.  After the OD of the ENU was calculated and 3 mM 
ENU in system water was prepared, each set of fish was transferred with their insert into 
the 3 mM ENU treatment water.  Fish were bathed in this treatment water for 1 hour in a 
quiet and dark fume hood.  After 1 hour of 3 mM ENU treatment, the insert was carefully 
lifted and inserted into a subsequent water tank containing tricaine, a commonly used 
anesthetic for zebrafish.  Tricaine was added as a means to help calm the fish down after 
ENU treatment.  Fish were rinsed in this water for another hour in the quiet and dark.  
Fish were transferred to subsequent wash tanks for 1 hour at a time for 2 more rinses, 
totaling 1 ENU treatment bath and 3 rinses (Figure 4-2).  After rinsing, fish remained in 
the last rinse tank overnight in the fume hood to help reduce death that may be caused by 
immediately transferring them back into system water
123
.   
 
The fish’s health was checked the following morning and then they were 
transferred back to the fish facility in a large tank with fresh tricaine wash water.  A 
cardboard box was placed over the tank during transport to maintain a dark environment.  
Males would be set up for matings on Monday following ENU treatment and then treated 
with ENU on Thursday.  This would help the fish get accustomed to mating for future 
breeding of the F1 generation.  ENU treatment was done once weekly over the course of 
three weeks. 
 
 
F1, F2, and F3 Generations 
 
After three weeks of rest, the surviving ENU males, labeled A through I, were 
mated to wild-type Tg(glut1b:mCherry ;fli1a:EGPF) females.  These offspring were the 
F1 generation and labeled with the letter of their original male father and spawn date.  625 
fish were produced for the F1 generation, were raised to a reproductive age, and then 
were mated to one another initially or wild-type Tg(glut1b:mCherry;fli1a:EGFP) animals 
to produce F2 families.  F2 families were labeled with a number starting at 001, the letter f 
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Figure 4-2. ENU treatment paradigm for male Tg(glut1b:mCherry;fli1a:EGFP) 
Founder males were treated with 3 mM ENU once a week, for three weeks total.  After 
each isopack of ENU was prepared and treatment water was made at 3 mM ENU, fish 
were immersed in the ENU solution for 1 hour in a quiet and dark fume hood.  After the 
treatment incubation, fish were transferred with an insert to subsequent tanks for washing 
in a 1 mM NaPO4 solution containing anesthetic.  A total of 1 treatment and 3 washes 
were performed.  After the last rinse, fish remained in the last tank over-night until they 
were transferred back to the fish facility.   
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of the original F0 male that gave rise to their F1 parents, and their F2 spawn date.  Random 
matings between F2 pairs generated F3 progeny.   F2 pairs that spawned were isolated 
while their offspring were screened.  These individual pairs were given an additional 
number after their F2 family number as to track each pair.  For example, the 6
th
 pair from 
family 022 was labeled as pair 22.6.  F3 progeny were labeled with the same number as 
their isolated F2 parents but their plates noted them as F3 and their spawn date.  At least 
six successful paired matings within a F2 family were performed to optimize the chance 
of finding heterozygous pairs for a given mutation in each family. 
 
 
F3 Progeny Screening 
 
F3 clutches were treated with PTU made in egg water to restrict pigmentation and 
make scoring fluorescence easier.  The F3 generation was visually inspected under bright 
field during early development and assessed for GFP and mCherry expression in the BBB 
at 4 dpf.  4dpf was chosen because mCherry expression increases in intensity from 30hpf 
onward and is easily visualized by 4 dpf without maternal contribution.  mCherry was 
also present in the heart of transgenics which helped served as an internal control for 
mutations that would affect the folding and expression of just the mCherry protein.  150 
µL of tricaine was added to each F3 dish before visual inspection under a Nikon SMZ 
1500 stereoscope with a PRIOR Scientific Lumen 200 PRO Fluorescence Illumination 
System.  Because we performed a forward genetic screen to identify recessive mutations, 
one-quarter of the F3 progeny would possess a mutant phenotype based on Mendelian 
probability if their F2 parents were heterozygous carriers for the same mutation.  
However, not all mutants were found at this ratio as phenotypic penetrance is not always 
Mendelian
124
.   
 
 
Mutant Imaging 
 
4-5 dpf mutant and wild-type sibling larvae were anesthetized in 0.04% tricaine 
made in PTU.  After fish were asleep, they were embedded with 1.2 % low-melting point 
agarose in a 35 mm glass bottom petri dish (MatTek).  Dorsal z-stack confocal images 
were acquired in St. Jude Children’s Research Hospital Cell and Tissue Imaging Facility 
on the Nikon C1Si microscope.  Images were acquired with either a 20 X lens or a 10 X 
lens and a 1.5 X zoom added in the Nikon C1Si software.  Each slice was 4 µm thick.  
 
 
Results and Discussion 
 
 
Fish Survival and ENU Efficacy  
 
Of the 23 original treated males, 9 males survived and were assigned a letter A- I.   
This 39% survival rate falls slightly lower than the realm of what is expected with a 3 by 
3 mM ENU treatment regimen
120
.  There are many factors that can induce death during 
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and after ENU treatment, including environmental disturbance of light and sound during 
treatment, fish developing startling responses, an ineffective dose of anesthetic, 
hypersensitivity after treatment to noise and vibrations, and removing a dead fish during a 
hyper-sensitive period
118
.  Even though we tried to avoid these issues and had a survival 
rate lower than 50 %, ENU teratogenicity was effective in subsequent generations.   
 
To check for the potency of ENU treatment, males were mated to wild-type 
females and the offspring was observed for phenotypes with mosaic mutation.  As seen in 
(Figure 4-3), just after one round of 3 mM ENU treatment, a portion of offspring from 
treated males developed abnormally and no longer expressed EGFP from the transgenic 
background.  ENU founder males were also crossed to Casper females to try and perform 
a specific locus test for the nacre and roy alleles.  nacre mutants do not possess 
melanocytes and roy mutants do not possess iridophores
125
.  After multiple rounds of 
mating, not enough embryos were spawned after each trial and no nacre or roy larvae 
were identified.  After a month of recovery from the ENU treatment paradigm, males 
were bred to create the F1 generation.  Around 625 F1 fish were generated from out-
crossing males A-I.  188 F2 families were generated by F1 incrosses and 22 F2 families 
were generated from outcrossing a F1 to a wild-type Tg(glut1b:mCherry ;fli1a:EGFP).  
Fewer F2 families were generated from outcrossing an F1 to wild-type transgenics as a 
means to cover more mutated genomes.  From the 210 F2 families generated, 114 families 
survived but not all 114 families ended up having at least six pairs to mate or had equal 
sex ratios.   
 
 
BBB Mutants Discovered from Our Forward Genetic Screen  
 
Of the 68 screened families to date, 4 confirmed BBB mutant lines were identified 
and observed over the course of their development (Table 4-1).  Some features scored in 
bright field included edema, necrosis, brain hemorrhage, and death.  Mutants were 
identified by a change in barriergenesis by Tg(glut1b:mCherry) expression or a change in 
CNS angiogenesis development as indicated in Tg(fli1a:EGFP).  Because 
Tg(glut1b:mCherry) transgenics also have heart expression, heart mCherry in scored 
mutants served as an internal control for mutations that affect the overall folding of the 
mCherry protein.   
 
Families 040, 044, and 196 consisted of mutants with normal peripheral 
angiogenesis but Tg(glut1b:mCherry) expression was absent or ectopic (Figure 4-4B, D, 
and F).  These families had extreme cases of brain necrosis and a lack of CNS 
angiogenesis.  Because brain necrosis was observed prior to and during barriergenesis, 
this suggests as it has been previously, that signals from the brain milieu are responsible 
for development of a healthy BBB
32
.  Family 196 was also unique because mutants were 
identified with a reduction in Tg(fli1a:EGFP)
 
(Figure 4-4L ).  This suggests that the 
mutation may affect vessel development health and delicate vessels may in turn affect 
barrier properties.   
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Figure 4-3. Effectiveness of 3 mM ENU after the 1
st
 round of ENU treatment 
After only one round of 3 mM ENU treatment, a founder male out-crossed to a wild-type 
female produced a portion of developmentally abnormal embryos.  (A) Brightfield image 
of embryo with heart edema (arrow) and bent back (arrow head).  (B) Under GFP 
fluorescence, no fli1a:EGFP  transgenic expression is visible.  
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Table 4-1. Observation of mutant lines over the course of development    
 
 
 
Mutant Line 
Glut1 
expression 
BEC 
development 
Hemorrhage 
(dpf) 
Necrosis Edema Death (dpf) 
22.6 Highly reduced Reduced No No No - 
40.7 
Ectopic; few 
positive sprouts 
Minimal 
sprouting 
60% mutants; 
2 dpf in brain 
CNS Heart 6 dpf 
44.3 Highly reduced None 3 dpf in brain CNS Heart and eye 6-7 dpf 
196.1 Reduced Reduced No CNS Heart 5 dpf 
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Figure 4-4. CNS angiogenesis mutants identified from the forward genetic screen 
Families 040, 044, and 196 harbored mutants with very little to no CNS angiogenesis (H, J, and L) but normal peripheral 
angiogenesis.  44.3 and 196.1 mutants had some mCherry expression but it was ectopically expressed (D and F arrows) compared to 
their wild-type sibling clutchmates (C and E).   
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Family 022 contained mutants with abnormal CNS angiogenesis but also a 
reduction in Tg(glut1b:mCherry) expression (Figure 4-5B).  It has been shown in mice  
that genes important for BBB development affect GLUT1 expression and also CNS 
angiogenesis development
35,36,126
.  It was ideal to find mutants that have a reduction in 
Tg(glut1b:mCherry) even though they still do not have completely normal CNS 
angiogenesis.  Mutants like 22.6 further supports that barriergenesis can be affected 
separately from CNS angiogenesis even though these processes occur simultaneously. 
 
 
Conclusion 
 
We performed the first forward genetic screen to identify mutations that affect 
BBB development and maturation using our Tg(glut1b:mCherry) reporter line.  Survival 
of the F1 larvae may have been low due to the mutations that were generated from the F0 
males.  Dominant lethal mutations in the F1 generation may also eliminate the chance of 
finding heterozygotes in the F2 generation.  Just like previous screens, we looked for 
recessive mutations transmitted to the F3 generation.  Even though we were not able to 
confirm ENU efficiency with a specific locus test, we were able to show its efficacy after 
one round of treatment.  To date in this small-scale screen, we identified 4 BBB mutants 
consisting of CNS angiogenesis mutants as well as a mutant that had a reduction in Tg 
(glut1b:mCherry).  These two classes of mutants suggest a genetic signature exists for 
BECs versus peripheral vessels as well as signals that affect barrier properties separately 
from CNS angiogenesis.  Future endeavors include outcrossing mutant founder pairs to 
polymorphic strains, further characterization of each line, and cloning these mutants to 
identify regulators of CNS angiogenesis and barriergenesis.  Ultimately, understanding 
the importance of these genes in barriergenesis could provide new therapeutic targets to 
modulate the BBB for drug delivery and prevent BBB breakdown in CNS diseases.   
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Figure 4-5. Tg(glut1b:mCherry) mutant and control sibling identified from the 
forward genetic screen 
Family 022 harbored mutants with some degree of CNS angiogenesis (D) but a decrease 
in mCherry expression (B) compared to wild-type expression (A).   
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CHAPTER 5.    CLONING AND CHARACTERIZATION OF THE FIRST 
ZEBRAFISH BLOOD-BRAIN BARRIER MUTANT, 22.6 
 
 
Introduction 
 
 
Positional Cloning  
 
The surge of zebrafish forward genetic screens in the 1990’s advanced the 
identification of mutation induced phenotypes in the developing vertebrate
48,49
.  
Generating genetic maps with polymorphic markers allowed mutations to be identified 
through positional cloning 
127,128
.  Positional cloning, also known as bulk segregant 
analysis (BSA), utilizes the linkage of polymorphisms to mutant strains to identify the 
genomic region carrying the mutated loci that is causative for a mutant phenotype
129,130
.  
BSA therefore requires the outcross of the parental line carrying the genetic mutation to a 
polymorphic strain.  Subsequently, heterozygous parents from this hybrid generation are 
identified and genomic DNA is isolated from individual mutant and wild-type siblings 
from in-crossing hybrid heterozygous parents.  Different markers along the genome are 
analyzed between pools of the wild-type and mutant DNA until a region with fewer 
recombination events is uncovered.  Because recombination events occur between loci 
that are farther apart, lower levels of recombination in mutant DNA pools will occur 
where the mutation is linked.  A genomic interval that is linked to a mutation will have 
low amounts of recombination and co-segregate with the genetic strain where the 
mutation was initially introduced.  The resolution of the linked interval is dependent on 
the number of meiosis analyzed, where 1 centiMorgen is 1 recombination event in every 
100 meioses
130
.  Therefore, more meiosis are needed to define a smaller critical interval 
where a mutation will be mapped.  After cloning a mutant, studies to perform 
characterization of the mutated gene, RNA rescue, genetic complementation, and 
phenocopy with gene knock down are typically implemented
129
.  Positional cloning has 
been successful at identifying mutations responsible in a range of physiology including 
iron transport, gastrulation, and pigmentation genes conserved between zebrafish and 
humans
131-133
.   
 
 
Next Generation Sequencing 
 
BSA has been efficacious at isolating genes mutated in forward genetic screens 
but not every mutant in a forward genetic screen can be successfully cloned with this 
strategy
50,134
.  Positional cloning is quite time consuming and tedious if linked markers 
are not detected in the initial round of mapping.  To circumvent these complications, next 
generation sequencing (NGS) strategies have increased the ease of cloning mutants 
discovered in zebrafish forward genetic screens
135-137
.  As compared to BSA, fewer 
mutants are needed for NGS strategies to produce sufficient resolution for mutation 
identification
130
.  Pooled DNA from 20 mutants is adequate for NGS techniques as 
compared to a pool of 50 larvae that can resolve 1 centiMorgen in BSA
130
.   
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There are various NGS methods, including Whole Genome Sequencing (WGS), 
Whole Exome Sequencing (WES), and RNA-seq.  Each of these approaches has its own 
pros and cons depending on the type of data that can be generated.  Even though the 
whole genome and its regulatory regions are analyzed in WGS, over 90% of the zebrafish 
genome is non-coding and most causative mutations usually occur in altering exons or 
splice sites , making WES a very attractive method
130
.  RNA-seq allows the simultaneous 
analysis of expression differences but contains bias on the level and degree of tissue 
expression at the time RNA is extracted for use
130,138
.  Such methods produce a large 
amount of computational data and the appropriate expertise and software is necessary to 
complete the analysis.  Ultimately, NGS technology provides a new platform for efficient 
identification of mutants isolated in screens whereby prior genetic map linkage is not 
needed.   
 
 
Materials and Methods 
 
 
Identifying the 22.6 Mutant Line 
 
22.6 mutants were identified in our forward genetic screen with Tg(glut1b: 
mCherry; fli1a:EGFP) for BBB mutants.  In the 6th pair from the 22
nd
 F2 family 
generated from ENU treated male A, around one quarter of the F3 clutch had reduced 
mCherry expression on 4 dpf compared to siblings.  The 22.6 pair was crossed again to 
confirm Mendelian transmission of the recessively inherited phenotype that was seen in 
the first mating.   
 
 
Bulk Segregant Analysis 
 
In order to find genetic linkage to a chromosomal locus, 22.6 mutants were out-
crossed to the polymorphic Tubingen Longfin (TL) strain.  Upon sexual maturation, fish 
were in-crossed to find heterozygous carriers of the 22.6 mutant allele.  Screening was 
performed based on phenotypic observation of the Tg (glut1b: mCherry) transgene just as 
it was performed in the forward genetic screen to identify the original 22.6 pair.  A total 
of 35 individual wild-type or mutant larvae were collected in 100 % methanol.  Fish were 
then digested in digest buffer with proteinase K and genomic DNA was isolated with 70 
% ethanol.  Pooled genomic DNA samples were diluted 1:10 in deionized water for a 
mapping PCR.  Wild-type or mutant genomic DNA was added into an Invitrogen 
Accuprime Taq polymerase master mix.  Master mix was added to a 384 well stock 
primer plate which contained all of the polymorphic marker primer pairs from the 
Massachusetts General Hospital (MGH) panel
127
.  Samples were analyzed on a 4% 
agarose gel to look for recombinants.   
 
Primers for markers on linkage groups 3, 11, 14, 22, and 23 were ordered from 
Invitrogen for follow-up.  Markers surrounding these from the MGH panel were selected 
from the ZFIN website and were also used for the follow-up PCR on individual wild-type 
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siblings and mutant 22.6/TL.  PCR master mixes and parameters were the same as with 
pooled DNA.  Samples were analyzed again on a 4 % agarose gel to look for 
recombinants.   
 
 
Exome Sequencing 
 
Genomic DNA was isolated from 40 wild-type sibling and mutant larvae with the 
Qiagen Mag Attract HMW DNA kit.  Larvae were generated from five separate pairs 
from the original 022 family.  Genomic DNA was analyzed for concentration and purity 
using a nanodrop spectrometer.  This DNA was then submitted to the Hartwell Center at 
St. Jude Children’s Research Hospital.  Staff performed a double stranded DNA assay 
and captured 3 μg of genomic DNA for sequence capture.  The type of sequence capture 
used was the Agilent SureSelect Target Enrichment (in solution) Illumina Paired-End 
capture.  The array/library used was the Agilent SureSelect XT Mouse methylseq-post 
capture pool.   
 
 From the raw sequencing reads, the quality control, mapping and variant calling 
were performed using CLC Genomic Workbench v6.5 (CLC Bio, Denmark).  In brief, 
the reads were trimmed against the sequencing adapters, and only reads with a 
sequencing quality greater than 20 and a read length greater than 50 bp were retained.  
The filtered reads were then aligned to the zebrafish reference genome sequence (Zv9 
assembly, 2010), and the lists of single-nucleotide variants were generated.  To identify 
the causative mutation responsible for the 22.6 phenotype, Michael Wang in the Hartwell 
Center compared the variants with those of wild type for mutant-specific homozygous 
mutations that have impact on proteins, including nonsense, missense and essential splice 
mutations.  Michael identified a total of 44 mutant-specific mutations, two on 
chromosome 8 altering the amino acid sequences and one of them introduced premature 
stop codon in g-coupled protein receptor 124.   
 
 
Polymerase Chain Reaction (PCR) and Sequencing of Candidate 22.6 Mutations 
 
Primers were designed flanking the C2941T mutation (forward 
GCGGCGTCCCTCTAATCATA, and reverse ATGCCTAAACCGGTAGCTGT).  
Genomic DNA from 10 individual wild-type and 10 22.6 mutants was diluted 1:10 for 
PCR.  PCR was performed with Accuprime Taq polymerase.  After PCR, products were 
analyzed on a 1% agarose gel before purification.  20 μl of PCR product was purified 
with a Qiagen PCR purification kit.  Samples were then nanodropped and 40 ng of 
purified PCR was submitted for sequencing to St. Jude Children’s Research Hospital 
Hartwell Center.  An alignment of each individual wild-type or mutant sequence was 
performed against the gpr124 cDNA (complementary DNA) reference sequence found on 
the Ensembl database (ENSDART00000112331) in the DNASTAR Lasergene 9 
MegAlign software.  Samples underwent the same processing for the candidate alpha-2B 
adrenoceptor (adra2b) with Ensembl sequence ENSDART00000018663 and primers 
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flanking the A748G predicted mutation ( forward ATAAAGGTGGTGGCGAGTCA , 
and reverse GCCTTTGGTGTTCTTGCAGA ).   
 
 
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) of gpr124 
 
RT-PCR was performed on cDNA from 0- 5 dpf zebrafish.  RNA was extracted 
from 10 embryos per tube with 50µl Trizol.  Following Trizol extraction, RNA was 
recovered with a phenol chloroform spin, isopropanol and glycogen precipitation, and 
75% ethanol wash.  cDNA was synthesized after the Trizol RNA extraction by using an 
Invitrogen SuperScript III First Strand kit.  The same primers from sequencing the 
candidate 22.6 mutation were used for RT-PCR using the Invitrogen Accuprime Taq 
polymerase system and a Biorad C1000 Thermal Cycler. 
 
 
IHC 
 
22.6 mutant and wild-type sibling larvae were collected at 3 or 4 dpf in a 1.5 mL 
tube on ice and fixed in 4 % paraformaldehyde at 4 ° C overnight.  The next day, larvae 
were rinsed in phosphate buffered saline (PBS) three times for five minutes each on a 
nutator and then sunk in 30 % sucrose at 4 ° C overnight.  After fish rose to the top at the 
sucrose’s meniscus, they were removed and embedded in Optimal Cutting Temperature 
(OCT) medium in a plastic embedding mold.  12 μm coronal frozen sections were cut on 
a Leica cryostat.   
 
 Sections were outlined with a pap pen to prevent the transfer of liquid between 
positive and negative control sides.  Slides were then initially rinsed once in PBS, and 
then three times for five minutes each in PBST (PBS, 0.3% TritonX 100) in a slide 
chamber on a belly dancer mixer.  After rinsing, 5% goat serum with 1% bovine serum 
albumin block was added to sections for 1-3 hours.  Blocking and antibody staining was 
performed in a humidity chamber made out of a sandwich box with wet paper towels.  
Primary antibodies rabbit anti Glut at 1 1:200 (Novus Bio), mouse anti Claudin5 at 
1:200(Invitrogen), mouse anti GFP at 1:500(Invitrogen), and rabbit anti-GFP at 1:500 
(Invitrogen) were diluted in blocking serum and then added to the bottom half of the 
sections and incubated at 4°C overnight.  The top part of the slide contained the negative 
control sections which were never stained with primary antibody but only secondary 
antibody.  After incubation in primary antibody, slides were rinsed in PBST for 1 hour.  
Secondary antibodies were prepared in blocking serum (goat anti mouse 488, goat anti 
rabbit 488, goat anti mouse 555, and goat anti rabbit 555 all at 1:200, Invitrogen) and 
added to sections at room temperature for 2 hours.  Slides were rinsed for another hour 
and then cover-slipped and sealed for imaging.   
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Cascade Blue, Rhodamine, and Fluorescein  
 
A minimum of five 22.6/TL mutant and wild-type siblings at 4 dpf were injected 
IV (intravenous) with a 3,000 Da tracer called Cascade Blue (Invitrogen) or 10k Da 
Rhodamine into the common cardinal vein near the heart.  Tracers were allowed to get 
into circulation for around an hour post-injection and then representative animals were 
imaged.  Ten mutant or wild-type larvae from the same 22.6/TL clutches were incubated 
per well with 50 µM Fluorescein (Fluka) made in PTU water for 30 minutes at room 
temperature in the dark.  After incubation, larvae were briefly rinsed twelve times in 
clean egg water before embedding and imaging.   All microinjections were performed 
using a PV820 Pneumatic PicoPump (WPI).  Injection volumes were calculated using a 
0.01 mm Stage Micrometer (Fisher Scientific).Larvae were anesthetized with 0.04% 
tricaine made in PTU water, embedded in 1.2% low-melting point agarose on glass cover 
slip petri dishes, and were visualized on the Nikon AZ100 or Nikon C1Si confocal.   
 
 
Results and Discussion  
 
 
Identification of the 22.6 Line 
 
Our first BBB mutant was identified from the sixth pair in family 022, originating 
from ENU-treated male A.  Upon screening at 4 dpf for changes in Tg(glut1b:mCherry) 
expression, around a quarter of F3 22.6 larvae had little to no mCherry expression in the 
BBB compared to siblings.  mCherry heart expression was unaffected, suggesting that 
this phenotype was not due to a mutation affecting the reporter gene itself.  The mutant 
progeny from the original 22.6 pair did have a portion of embryos with brain hemorrhage 
on 4 dpf, a phenotype reported in the Gpr124 mouse knockout
35
.  However, when 22.6 
was out-crossed to TL and new heterozygous carriers were identified, the brain 
hemorrhage phenotype was no longer seen.   
 
 
Cloning the 22.6 Mutation, gpr124  
 
To try and clone 22.6, we performed BSA on pooled genomic DNA from wild-
type and mutant siblings while samples were correspondingly submitted for WES 
(Figure 5-1).  Both experiments were implemented so two independent methods could 
confirm identification of the mutant allele.   
 
We first performed the initial PCR on the full MGH panel.  After the gels were 
analyzed, another round of PCR was performed with follow-up markers on individual 
larvae.  Combing both techniques has successfully identified linkage and subsequent 
alleles in Xenopus tropicalis mutants
134
.  While this is an ideal strategy, positional 
cloning is not always guaranteed to work for every mutant.  For example, del Viso et al. 
(2012) were able to perform this dual approach on the ruby mutant but not on the grinch 
mutant
134
.  We were also unsuccessful at identifying a map position with BSA.  However,  
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Figure 5-1. Workflow comparison of bulk segregant analysis and exome 
sequencing for cloning zebrafish mutants from a forward genetic screen 
To clone mutants in our forward genetic screen, we wanted to utilize both bulk segregant 
analysis and exome sequencing.  (A) For genetic mapping, larvae must be out-crossed to 
a polymorphic strain to identify linkage in the background which carried the mutation.  
For genetic mapping, we analyzed pools of wild-type and mutant genomic DNA with the 
MGH mapping panel.  We then identified markers with possible linkage and obtained 
more primers surrounding those markers for a subsequent PCR.  (B) We simultaneously 
submitted wild-type and mutant genomic DNA to the Hartwell Center at St. Jude 
Children’s Research Hospital for exome sequencing.  Hartwell Center scientists used the 
Agilent SureSelect Target Enrichment Illumina Paired-End capture and further analysis 
was done with the CLC Genomic Workbench v6.5 and zebrafish reference genome 
sequence (Zv9 assembly, 2010) to identify a candidate mutation.   
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exome sequencing identified a guanine to adenosine point mutation at 39,116,104 bp on 
zebrafish linkage group 8 in the gpr124 locus (Table 5-1).  At the mRNA level, this 
causes a change from cysteine to thymidine at 2941 bp.  Because the transcript is in the 
reverse orientation, this C2941T mutation causes a premature stop codon in the protein.  
adra2b was also identified as a possible hit, but the point mutation in gpr124 seemed 
worth following up on first since the base pair changed caused a premature stop in the 
protein and gpr124 has been implicated in BBB development (Table 5-1)
34,35
.   
 
After identification of the point mutation, primers were designed flanking the 
C2941T mutation as well as the other candidate A748G mutation.  Genomic DNA from 
the original fish used for exome sequencing was individually amplified with the flanking 
primers, the PCR products were purified, and the samples were then sent off for 
sequencing.  Each individual wild-type larvae had a cysteine at position 2941in gpr124 
cDNA however in each of the mutants, there was a thymidine at 2941 as seen from a 
subset of the alignments (Figure 5-2A).  Furthermore, the A748G candidate in adra2b 
turned out to be a polymorphism, as a subset of wild-type siblings possessed a guanine at 
position 748 like the mutant samples (Figure 5-2B).  
 
 
Characterization of gpr124
-/- 
Mutants 
 
 
IHC with BBB Markers. The BBB is commonly characterized for its physical, 
chemical, and functional properties.  To assess these in the 22.6 mutant line, IHC and 
tracer injections were performed.  Other groups have shown effects on tight junctions and 
transporters in BBB mutants
35,36,102
.   Specifically, Cullen et al. (2011) showed that 
GLUT1 expression is disrupted in Gpr124
-/- 
mutant mice which agrees with the 22.6 
mutant model from our BBB screen
35
.  We knew that the mutation in gpr124 was 
predicted to cause a premature stop codon in the protein, but we wanted to know if the 
Glut1 protein was affected.  To assess if Glut1 protein was affected in mutant BECs, IHC 
was performed on transverse sections from larval 22.6/TL mutants.  As seen in sections 
from wild-type and mutants, the expression level of Glut1 protein was not different 
(Figure 5-3A).  We also wanted to see if tight junctions were mis-expressed since 
hemorrhage was originally seen in 22.6 but not in 22.6/TL mutants.  To do this, we 
performed IHC with a monoclonal Claudin5 antibody on transverse sections from larval 
22.6/TL mutants.   
 
 
Table 5-1. Candidate mutations for the 22.6 line 
 
Gene 
name 
Chromosome Position Reference Mutation mRNA Protein 
gpr124 chr8 39116104 G A 2941C>T p.Gln981* 
adra2b chr8 42259829 T C 748A>G p.Thr250Ala 
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Figure 5-2. Sequencing larvae for the 22.6 candidate gene mutations 
(A) Primers flanking the C2941T mutation were used to amplify genomic DNA from 
individual larvae that were used for exome sequencing.  A 1200 bp product was 
amplified from both wild-type and mutant samples.  After PCR products were purified, 
they were sent off for sequencing with the same primers used in the PCR amplification.  
Sample sequences were aligned to a gpr124 cDNA reference sequence.   Alignments 
revealed that, as predicted, the wild-type samples possessed a C at position 2941 while 
each of the mutants possessed a T.  (B) Similarly, PCR was performed with primers 
flanking the predicted A748G adra2b mutation.  The 971 bp PCR product was sent off 
for sequencing with the same PCR primers.  As confirmation that gpr124 was mutated 
and not adra2b in our 22.6 line, alignment against adra2b cDNA revealed that the 
A748G base change was a polymorphism.  While all mutant samples contained a G at 
position 748, some wild-type samples contained a G at position 748 as well.  
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Figure 5-3. Immunohistochemical analysis of BBB markers Glut1 and Claudin5 
in 22.6 mutants and wild-type siblings  
Antibody staining for Glut1(A) and Claudin5(B) proteins was performed to identify any 
differences between 22.6 mutant and wild-type sibling BBB protein marker expression.  
Staining revealed that at the protein level, there was no difference in the intensity of 
Glut1 or Claudin5 expression even though there are fewer BECs in the mutants as seen 
with GFP staining.   
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Just as with the Glut1 protein, we did not see any difference at the protein level with the 
Claudin5 antibody in 22.6 mutants (Figure 5-3B).  The expression of Claudin5 may not 
have been affected due to compensation from other tight junction proteins.  Also, 
Claudin5
-/-
 mice do not experience brain hemorrhage but a “size-selective” leakiness 
when injected with tracers suggesting lack of Claudin5 does not cause brain hemorrhages 
but a selective opening of the barrier
22
.  Furthermore, signaling pathways important for 
barriergenesis, like Wnt signaling, affect Claudin5 expression but not Occludin or ZO-1 
demonstrating distinct target genes among proteins that have similar functions in the 
barrier
36,102
.   
 
 
Functional Studies with Tracers. We no longer saw brain hemorrhages in the 
outcrossed 22.6/TL line but still wanted to see if mutant vessels were leakier than wild-
type since Gpr124 
-/-
 mice have brain hemorrhages
35
.  To assess the function of the BBB 
in 22.6/TL mutants, fluorescent tracers were injected into circulation or bathed on 
22.6/TL mutants and wild-type siblings.  After IV injection, Cascade Blue, a 3,000 Da 
tracer leaked into the mutant brain greater than in wild-type larvae (Figure 5-4).  We then 
wanted to see if this leakiness would still hold true with a tracer smaller and larger than 
Cascade Blue.  The BBB of 22.6/TL also showed leakage with 10 kDa Rhodamine and 
332 Da Fluorescein tracers (Figure 5-5).  While the 22.6/TL mutants did not have 
hemorrhages, we still saw leakage with tracers smaller than large plasma proteins like the 
78 kDa Vitamin-D binding protein which is a member of the zebrafish albumin family
62
.  
Interestingly, while Rhodamine gets into the brain parenchyma of 22.6/TL, it appears as 
if the blood-CSF barrier is still intact (Figure 5-5A arrows).   
 
 
Conclusion 
 
The 22.6 mutant line was the first mutant identified from our BBB forward 
genetic screen.  To clone this line, we simultaneously performed BSA and NGS 
experiments.  Like other groups, we did not get a successful map position with BSA but 
were able to clone 22.6 with WES
134
.  WES revealed a point mutation in the gpr124 
allele which in turn was predicted to cause a premature stop codon in the protein 
sequence.  Gpr124 has already been shown to be important for BBB development in 
mammals and therefore cloning this mutant validates the authenticity of our screen to 
find BBB mutants
34,35,126
.  In order to investigate the structure of the 22.6 BBB, we 
looked at Claudin5 expression in mutant BECs.  We did not notice a change in protein 
levels for Claudin5 in mutants compared to wild-type siblings.  We also observed a size-
selective leakiness in mutants with a 3000 Da Cascade Blue but not a 10 kDa Rhodamine 
tracer.  While the protein level of Glut1did not dramatically decrease in sections, it is 
hard to quantify expression level from sections.  Also, Tg(glut1b:mCherry) was not 
completely absent in the 22.6 line as seen by confocal microscopy.  Ultimately, cloning a 
gpr124 zebrafish mutant will provide the BBB community with another tool to study 
barriergenesis.  Furthermore, g-coupled protein receptors are highly targeted in drug 
discovery and finding the gpr124 ligand may now be easier with this zebrafish mutant 
and model
139
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Figure 5-4. 22.6/TL mutants appear “leaky” after IV injections with Cascade 
Blue 
4 dpf Wild-type and 22.6 mutant siblings were injected with Cascade Blue, a 3,000 Da 
tracer into the common cardinal vein.  After tracers were in circulation for 1 hour, larvae 
were imaged on the Nikon AZ100.  As compared to wild-type (D), two representative 
mutants had increased fluorescence in the blue channel (I, N).  This “leakier” 22.6 
phenotype may be attributed to the fact that there are less vessels in the mutant (H, M) 
compared to wild-type siblings (C) as captured with GFP.  
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Figure 5-5. The 22.6/TL mutant blood-brain barrier is leaky with various sized 
tracers 
4 dpf wild-type siblings and 22.6/TL mutants were either injected with 1 nl 10 kDa 
Rhodamine (A) or bathed for 30 minutes in 50 µM Fluorescein (B).  Confocal imaging 
revealed that mutants have more leakage of each tracer into the brain (A arrowhead; B 
arrow).  Even though Rhodamine gets into the brain parenchyma of 22.6/TL, it appears 
as if the blood-CSF barrier is still intact (A arrows).   
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CHAPTER 6.    A CHEMICAL SCREEN TO IDENTIFY MODULATORS OF 
BLOOD- BRAIN BARRIER DEVELPOMENT  
 
 
Introduction 
 
 
Importance and Classification of Chemical Screens 
 
The development of new therapeutics has large cost and time implications in the 
management of health issues.  It is estimated that developing a new drug takes 12-15 
years with over $1 billion in costs
140
.  It is also important to sufficiently validate targets 
during lead drug discovery as this is one reason why drugs fail to work in the clinic
140
.  
With an advanced understanding in disease etiology and possibilities for therapeutic 
targets, small molecule discovery is an extremely prevalent avenue for the development 
of new drugs.  Small molecule screens, which are more cost-effective and faster assays, 
haven been known to make a big impact on drug discovery such as in the field of cancer 
biology
141
.   
 
While it is imperative to advance the field of medicine with new compounds 
because of issues like antibiotic and chemotherapeutic resistance, small molecule screens 
may effectively repurpose drugs.  This type of approach referred to as a “connection 
screen” takes well-characterized drugs and identifies compounds that regulate a 
biological process of interest 
142
.  Other kinds of screens include targeted, phenotypic, 
disease modifier, and library annotation.
142,143
  Targeted screens utilize genetic reporters 
and readout such as fluorescence is monitored.  Secondary assays and follow-up with 
dose response curves are essential in showing the effectiveness of a chemical hit from a 
targeted screen
143
.  Phenotypic screens are assays without any previous knowledge of the 
target, but many unrelated biological factors can go into affecting the phenotype
143
.  One 
of the drawbacks in a phenotypic screen is the lack of known mechanism.  Because 
compounds may not be extremely selective, a phenotype may not be caused by a small 
molecule binding to a suggested target
143
.  However, many drugs have been successfully 
developed by phenotypic screens
57
.  As a kind of genetic model, disease models may be 
created in order to find small molecules that target a pathway of interest.  Disease 
modifier screens test small molecule libraries in order to try and rescue or reduce the 
progression of particular disease phenotypes.  Lastly, library annotation screens take 
novel compounds and characterize them based on the phenotype that is produced in the 
screen assay.  These screens help characterize newly synthesized compounds that may be 
very functionally diverse
142
.  Regardless of the kind of screen, each of these can be 
performed in the zebrafish model depending on the hypothesis that needs to be tested. 
 
 
Chemical Screens in Zebrafish 
 
Zebrafish are an ideal organism for small molecule screens as they are a cost-
effective model, develop rapidly outside of the mother, are translucent in early 
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development, high clutch numbers can be timed when generated, and are small enough to 
be used in a high- content and throughput fashion.  If later stages are to be analyzed, 
pigmentation can also be prevented by treating with the chemical PTU
142
.  Individual 
embryos can be placed in 96 and even 384 well plates and the embryos will still develop 
normally over time (Figure 6-1).  Embryos and larvae can be staged prior to the 
developmental window that is desired for testing.  Zebrafish can then be delivered to 
wells, embryo water may be carefully removed, and the desirable amount of drugging 
water can be added back or fish may be delivered to plates in a pre-designated volume.  
Drugs can then be added to the zebrafish after the pre-designated volume of water is 
added so as to result in a particular final concentration of drug.  Depending on the stage 
that is to be screened, zebrafish incubate in the compounds for a period of time until they 
are phenotypically observed.   
 
Small molecule screens can also supplement genetic screens which are commonly 
performed in zebrafish.  Hits may modulate paralogs in the zebrafish genome that 
resulted from the genome duplication
46,142
.  Transgenesis is also a common technique 
applied to the zebrafish which can easily be used in targeted screens.  For example, the 
commonly used vascular reporter, Tg(fli1a:EGFP)
 
was used in a small molecule screen to 
identify compounds that effect development of the vertebrate retina
144
.  Cells extracted 
from transgenic zebrafish may also be cultured in vitro and used to screen a higher 
volume of compounds
145
.  However, the advantage of using the zebrafish is that behavior 
and physiological development of a vertebrate can be monitored versus the fewer and 
broader phenotypes assayed in in vitro systems.  Absorption, distribution, metabolism, 
and excretion studies have not been established in zebrafish yet, but hydrophobicity as 
measured by logP values can predict bioavailability in zebrafish treated with compounds 
with various molecular weights
146
.  Zebrafish have been a successful model to repurpose 
drugs and studies have validated zebrafish small molecule screen hits in mice as well
147
.   
 
 
Materials and Methods 
 
 
Chemical Libraries Tested 
 
Because of its availability in our department and clinical significance, the Food 
and Drug Administration (FDA) library was the first library we tested.  Subsequent 
screens were done with the ENZO Wnt, Autophagy, and Neurotransmitter libraries.  The 
ENZO libraries were tested with the help of Dr. Steven Finckbeiner. 
 
 
Staging, Dosing, and Screening Strategy 
 
For the FDA library screen, zebrafish matings were set-up between Tg 
(glut1b:mCherry; fli1a:EGFP) males and TL females two days prior to drugging.  
Matings were timed so that embryos could be staged the next day.  After the plates were 
void of unfertilized embryos, embryos were rinsed into a 1% Dimethyl sulfoxide  
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Figure 6-1. Zebrafish embryos are amenable for high-content small molecule 
screening 
Multiple zebrafish embryos can be staged and easily placed into 96-well plates for 
chemical screens.   
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(DMSO) solution.  Three embryos per well were plated in the 1% DMSO water onto a 
Perkin Elmer Cell Carrier black plate under the aid of a Nikon SMZ 1500 stereoscope.  
On drugging day, wells were checked for unfertilized eggs , water was removed, and 90 
µL of 1% DMSO, PTU egg water was added to the wells.  We used PTU water to prevent 
pigmentation in the animals and make fluorescence screening at 3 dpf easier.  An initial 
screening dose of 10 µM was used in the FDA screen as that is a reasonable 
concentration in zebrafish small molecule screens
142
.  10 µL of compound was 
transferred with a multichannel pipette from a 384 well drug library plate to the 90 µL in 
the 96 well plate containing the 24 hpf zebrafish embryos.  This produced a 1:100 
dilution from a 100 µM stock plate, resulting in the final dosing concentration of 10 µM.  
Column 1 was always a negative control, containing fish in 1% DMSO water only.  
Column 7 was always a positive control, containing 2 µM Tunicamycin, a drug that we 
previously found caused brain hemorrhage and reduced BEC development.  After 
drugging, plates were placed in a humidity chamber which consisted of moistened paper 
towels in a sandwich box.  This box containing the drugged embryos was placed in the 
28.5°C incubator.  The incubator was on a 10 hour light 14 hour dark cycle like the 
zebrafish facility.  Wells were monitored at 2 dpf under brightfield to look for any 
abnormal development such as CNS necrosis or brain hemorrhage.  At 3 dpf, embryos 
were assessed under brightfield optics as well as mCherry and GFP on a Nikon SMZ 
1500 stereoscope with a PRIOR Scientific Lumen 200 PRO Fluorescence Illumination 
System.  To score for changes in BBB development, embryos were anesthetized with 
0.04 % tricaine, around 300 µL of cooled 1.2 % low-melting point agarose was added to 
each well, the agarose hardened, and then plates were flipped upside down so that larvae 
were now stationary at the bottom of the 96 well plate for screening.  Images were also 
recorded on the GE InCell 6000 in the High-throughput Screening core in the Chemical 
Biology and Therapeutics Department. 
 
For the ENZO library screens, matings were set up like they were for the FDA 
screen.  At one point, we switched to using Tg(glut1:mCherry) males by Tg(fli1a:EGFP)
 
females to try and increase clutch size and the number of crosses we could set up.  This 
time, embryos were cleaned but not plated until drugging at 24 hpf.  For plating, embryos 
were rinsed from egg water into PTU and then into 1 % DMSO water made in PTU.  We 
also tried a range of doses for this library consisting of a 100, 10, and 1 µM dose for each 
compound plate.  3 embryos were transferred with either 198 or 180 µL 1 % DMSO, 
PTU water into the 96 well plates.  The range of doses was carried out in a serial dilution 
on the Tecan Freedom Evo in the Chemical Biology and Therapeutics Department.  
Embryos in plate one had 198 µL of water and 2 µL of stock compound added for a final 
concentration of 100 µM.  20 µL from this 100 µM plate was transferred by the Tecan to 
plate two with 180 µL to make a 10 µM plate.  Another 20 µL from the 10 µM plate was 
transferred by the Tecan to the third plate with 180 µL to make the 1 µM plate.  Negative 
controls were in column 1, consisting of embryos in 1% DMSO, PTU water only.  
Positive controls were in column 7 and consisted of 100, 10, or 1 µM DMH4, a potent 
angiogenesis inhibitor, or 20, 2, or 0.2 µM Tunicamycin for plates one, two and three, 
respectively
105
.  Plates were scored on 2 dpf and 3 dpf just as they were for the FDA 
library screen (Figure 6-2).   
 
  66 
 
 
 
Figure 6-2. Weekly workflow for the blood-brain barrier chemical screen 
Zebrafish matings were timed between Tg (glut1b:mCherry;fli1a:EGFP) males and TL 
females or Tg (glut1b:mCherry) males and Tg(fli1a:EGFP)
 
females.  Embryos were 
collected and rinsed the next day.  On drugging day, embryos were staged at 24 hpf in 
black bottom 96 well plates.  Compounds were added to the 96 well plates already 
containing the zebrafish.  At 2 dpf embryos were scored qualitatively for developmental 
abnormalities and scored again at 3 dpf for the same abnormalities as well as changes in 
reporter gene expression.   
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Statin Dose Response Testing 
 
Each of the 10 statins were tested for a dose response on 24 hpf embryos.  The 
range of doses went from 100 μM down to 100 nM decreasing stepwise in a factor of 3.  
The dose responses for all 10 statins were repeated three times.  Statins were acquired 
from Compound Management in the Chemical Biology and Therapeutics department.  
Statin stocks were in 100% DMSO and diluted into 1% DMSO, PTU egg water during 
treatment.  Zebrafish were monitored for CNS necrosis, brain hemorrhage, and death at 
each dose from 24 to 48 hpf. 
 
 
Tunicamycin, Forskolin, and GBR13069 Treatment 
 
24 hpf Tg (glut1b:mCherry; fli1a: EGFP) embryos were dosed with 1 µM 
Tunicamycin, which blocks N-linked glycosylation, 1- 10 µM Forskolin, which elevates 
cyclic adenosine monophosphate (cAMP), and 100 – 6.25 µM GBR13069, a dopamine 
uptake inhibitor.  All compound stocks were in 100 % DMSO and diluted in 1% DMSO, 
PTU water for treatment.   The GBR13069 dose response was performed by Dr. Steven 
Finckbeiner.   
 
 
Dolichol Kinase (dolk) Morpholino Injections and RT-PCR 
 
1 nl of a 0.5 mM start site morpholino (TAAACATTGTCCACTTCTTGTCCTC) 
was injected into the cell of Tg(glut1b:mCherry; fli1a: EGFP) embryos at the single cell 
stage.  Embryos were monitored over development and scored at 2 dpf for hemorrhages. 
All microinjections were performed using a PV820 Pneumatic PicoPump (WPI).  
Injection volumes were calculated using a 0.01 mm Stage Micrometer (Fisher Scientific).  
 
RT-PCR was performed on cDNA from 0-5 dpf zebrafish.  RNA was extracted 
from 10 embryos per tube with 50µl Trizol.  Following Trizol extraction, RNA was 
recovered with a phenol chloroform spin, isopropanol and glycogen extraction, and 75 % 
ethanol wash.  cDNA was synthesized after the Trizol RNA extraction by using an 
Invitrogen SuperScript III First Strand kit.  PCR was performed with dolk (forward, 
GTTGAATCTGCGGTGGTGTT and reverse, CAATCCCAAAACCGCAGTCA) and 
actin (forward, TGAATCCCAAAGCCAACAGAG and reverse, 
TCACACCATCACCAGAGTCC ) primers using the Invitrogen Accuprime Taq 
polymerase system and a Biorad C1000 Thermal Cycler.   
 
 
Microscopy 
 
After treatment or injection, larvae were observed and stage selected for 
microscopic documentation.  Fish were anesthetized with 0.04 % tricaine and then 
embedded dorsal side down in 1.2 % low-melting point agarose in a glass coverslip 
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bottom petri dish.  Confocal images were acquired together for brightfield, mCherry and 
GFP on the Nikon C1Si.  Brightfield z-stack images were acquired on the Nikon AZ100.   
 
 
Results and Discussion 
 
 
FDA Library Chemical Screen Hit: Statins 
 
From the FDA library, six 384 well plates were tested totaling 884 compounds.  
The library was added to 24 hpf Tg(glut1b: mCherry; fli1a: EGFP) embryos to bypass 
any effects on initial development but to still target development prior to CNS 
angiogenesis at 30 hpf.  Our most penetrant hit was a class of compounds known as  
statins.  Statins are commonly given to patients for lipid lowering therapy to help prevent 
coronary heart disease and are well developed inhibitors of the rate-limiting enzyme in 
cholesterol biosynthesis, HMG-CoA reductase
148
.  Rosuvastatin, a commonly prescribed 
statin, was actually found as an anti-angiogenic inhibitor in another zebrafish chemical 
screen, but compounds in that study were added at 20 hpf before intersegmental vessels 
formed in the embryo
60
.  Outside of early development, statins are also known to have 
beneficial side effects in neurological disorder therapy via pleiotropic effects on 
downstream isoprenoid synthesis
149
.   
 
 To our surprise, we found that depending on the statin, embryos developed brain 
hemorrhage and/or CNS necrosis at 2 dpf and even death after 24 hours of exposure 
(Figure 6-3).  Dose responses were repeated three times for each statin and a heat map 
was generated to depict the half maximal effective concentration (EC50) for each statin  
 (Figure 6-4).  As depicted in this heat map for a selection of the statins tested, more 
lipophilic compounds such as Simvastatin caused severe side effects at lower EC50s 
compared to less lipophilic statins like pravastatin.  In fact, hemorrhage was seen as high 
as 30 μM pravastatin but as low as 100 nM with simvastatin.  Pravastatin was not 
originally a hit in our FDA screen because the 10 μM dose we used for screening was too 
low to cause hemorrhage in the zebrafish.  This result is congruent with the BBB 
literature, reiterating that lipophilicity is one of the drug qualities that affect BBB 
penetration
5
.  Statins also vary at the pharmacokinetic level when it comes to 
bioavailability and cytochrome p450 drug metabolism, suggesting another mechanism for 
the different effects among this class of drug
148
.   
 
 We then wanted to know if CNS angiogenesis would only be affected if treatment 
was performed before or after 24 hpf.  Our lab and others have shown that the BBB 
develops early in the zebrafish, but we wanted to know if statins still have an effect on 
CNS angiogenesis in a zebrafish after the initiation of barriergenesis
62
.  To answer this 
question, a time course with 1 µM Atorvastatin and 10 µM Rosuvastatin was performed 
as outlined in (Figure 6-5).  For treatments done before 4 hpf prior to zygotic 
transcription, larvae at 2 dpf had a reduction in CNS angiogenesis (Figure 6-6, top 
panel).  Interestingly enough as seen with a well-known inhibitor of angiogenesis, statins  
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Figure 6-3. Statins induce cerebral hemorrhage and reduce CNS angiogenesis in 
the developing zebrafish 
Compared to untreated siblings (B), Tg (glut1b:mCherry; fli1a:EGFP) embryos treated at 
24 hpf  with 1 µM Atorvastatin (G) or 10 µM Rosuvastatin (L) had reduced CNS 
angiogenesis.  Levels of mCherry expression in statin treated embryos (F, K) were still 
similar to control (A).  Statin treated embryos also developed cerebral hemorrhages as 
seen in dorsal views (I, N arrows) and side views (J, O arrows) unlike their untreated 
siblings (D, E).   
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Figure 6-4. Zebrafish as a predictive indicator of blood-brain barrier penetration 
of statins 
Depending on the lipophilicity of the statin, zebrafish developed an array of phenotypes 
ranging from brain hemorrhage to death.  More lipophilic statins like simvastatin cause 
more severe side effects at lower doses versus a less lipophilic statin like pravastatin.    
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Figure 6-5. Experimental design for a developmental time course with 
Atorvastatin and Rosuvastatin treatments 
Tg (glut1b:mCherry; fli1a:EGFP) embryos were treated with 1 µM Atorvastatin or 10 
µM Rosuvastatin and then imaged throughout the course of development to see if the 
effects of statins still persisted before or after the initiation of barriergenesis. 
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Figure 6-6. Statin treatment prior to zygotic transcription disrupts CNS 
angiogenesis 
Tg (glut1b:mCherry; fli1a:EGFP) embryos were treated with 1 µM Atorvastatin or 10 
µM Rosuvastatin before 4 hpf.  The top panel shows that by 2 dpf, CNS angiogenesis is 
disrupted in statin treated fish (E, H) compared to untreated siblings (B).  Interestingly, 
the PHBCs of statin treated embryos still undergo barriergenesis as indicated by glut1b 
expression (F, I arrows) even though CNS angiogenesis is abnormal.  The lower panel 
shows that by 3 dpf, larvae have an even more severe reduction in CNS angiogenesis 
after incubating in statins for a longer period of time.  Treated embryos also seem to 
express glut1b ectopically in the brain (D, G). 
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delivered less than 4 hpf prevent CNS angiogenesis but still allow glut1b positive PHBC 
development to occur (Figure 6-6F and I, top panel arrows).   Embryos that incubated in 
statins for another 24 h until 3 dpf had a more severe effect on brain vasculature 
development and glut1b even seemed to be ectopically expressed (Figure 6-6D and G, 
bottom panel)  For treatment performed at 24 or 48 hpf until 72 hpf, statins still 
disrupted the development of the brain vasculature (Figure 6-7).  While CNS 
angiogenesis was disrupted when treatment was done after 2 dpf (Figure 6-7E and H, 
bottom panel), treatment performed at 24hpf until 72 hpf had a more severe effect on the 
development of BECs (Figure 6-7E and H, top panel).  Treatment done later from 5 dpf 
onward did not produce any brain hemorrhage in the developing larvae.   
 
While a developmental time course of statin treatment had not been performed in 
the zebrafish, other groups have previously demonstrated brain hemorrhage induced by 
statins during the time we were performing our FDA screen
150,151
.  These groups 
suggested hemorrhage was due to inhibition of protein prenylation and absence of 
Coenzyme Q10.  While these hypotheses were validated, the cholesterol biosynthetic 
pathway affects another major downstream biochemical process, N-linked glycosylation.  
For our small molecule screens we had been using Tunicamycin, a well-known inhibitor 
of N-linked glycosylation, as a positive control.  As seen after 1 μM Tunicamycin 
treatment at 24 hpf, embryos developed brain hemorrhages and had abnormal CNS 
angiogenesis just like statin treated embryos (Figure 6-8).  To try and draw a mechanistic 
connection between statin-related brain hemorrhage and abnormal vessel development, 
we decided to knock down dolk with morpholino technology.  Dolk is an enzyme active 
at the endoplasmic reticulum, important for N-linked glycosylation, and is upstream of 
Tunicamycin’s target.  By knocking down dolk, we could investigate whether our 
chemical treatment could be phenocopied genetically with morpholinos.  While not 100% 
penetrant, 1nl of a 0.5 mM dolk start site morpholino injection produced brain 
hemorrhage in 10-15% of morphants as well as abnormal CNS angiogenesis 
(Figure 6-9B, C).  Hemorrhage was also seen at a higher dose of 1nl of 1 mM 
morpholino.  Morphants also developed a smaller, dented head, curved tails, heart edema, 
and had heartbeat without circulation.  Because dolk is maternally derived (Figure 6-9A), 
this may contribute to the low penetrance of brain hemorrhage especially since the 
morpholino becomes more dilute over time.  The diffusion of the morpholino may also 
explain why the reduction in CNS angiogenesis in dolk morphants was not as severe as 
chemical treatment was with Tunicamycin.  Similar to statin treatment after 24 hpf, the 
dolk morpholino did not disrupt peripheral angiogenesis (Figure 6-10).   
 
 
ENZO Wnt and Autophagy Library Hit: Forskolin 
 
For the ENZO libraries, we started off with the Wnt and Autophagy compounds.  
Wnt is known to be important for barriergenesis as well as a regulator of Glut1 
expression, so it was expected to find hits from this library
36,102
.  To our surprise, 
Forskolin was a hit common to both the Wnt and Autophagy libraries.  Forskolin is a 
well-known inhibitor of cAMP production.  When dosed at 24 hpf ,10 μM Forskolin 
caused abnormal CNS angiogenesis, extreme kinking of the tail, and seizure-like  
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Figure 6-7. Statin treatment from 24 or 48 hpf to 72 hpf disrupts CNS 
angiogenesis 
Tg (glut1b:mCherry; fli1a:EGFP) embryos were treated with 1 µM Atorvastatin or 10 
µM Rosuvastatin at 24 or 48 hpf until 72 hpf.  The top panel shows that by 3 dpf, CNS 
angiogenesis is disrupted in statin treated fish (E, H) compared to untreated siblings (B) 
when embryos incubate in compound for 2 days.  The lower panel shows that later 
treatment at 48 hpf still causes a reduction in CNS angiogenesis (E, H) albeit less severe 
than statin treatment at 24hpf for 48 hour exposure. 
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Figure 6-8. Tunicamycin causes a similar disruption to CNS vessels as does statin 
treatment 
Tg (glut1b:mCherry; fli1a:EGFP) embryos were treated with1 μM Tunicamycin at 24 
hpf.  The next day after treatment, embryos developed hemorrhages in the brain (A, 
arrow) and ventricle (A, arrow head) similar to what was seen with statin treatment.  
Confocal microscopy revealed that CNS angiogenesis was also disrupted in Tunicamycin 
treated embryos (B). 
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Figure 6-9. dolk is maternally derived and disrupts CNS angiogenesis when 
targeted with morpholinos 
RT-PCR was performed for the dolk transcript on 0 – 5 dpf cDNA (A).  1nl of a 0.5 mM 
dolk start site morpholino caused 10-15% of morphants to develop brain hemorrhages at 
2 dpf (B).  Confocal microscopy revealed abnormal CNS angiogenesis in morphants 
compared to un-injected siblings (C). 
 
 
 
 
 
 
 
 
  77 
 
 
 
Figure 6-10. dolk morphants have normal peripheral angiogenesis 
Knockdown of dolk in Tg(glut1b:mCherry; fli1a:EGFP) embryos does not affect the 
development of peripheral endothelium (E ) compared to the development in un-injected 
control siblings (B).   
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behavior (Figure 6-11).  It is not known whether the spastic behavior of the Forskolin 
treated fish was neuro-muscular or seizure-induced but it was a very pronounced 
phenotype.  A dose response with Forskolin also showed a dose-dependent phenotype for 
this compound (Figure 6-11B).   
 
 
ENZO Neurotransmitter Library Hit: GBR13069 
 
The BBB maintains critical interactions with the cells of the NVU.  Groups have 
investigated the role of astrocytes and pericytes, but not a lot has been published on the 
contribution of neurons to barriergenesis
27,33,41
.  To test the impact of NTs during BBB 
development, agonists and antagonists of common NTs were added to developing Tg 
(glut1b:mCherry; fli1a:EGFP) embryos at 24 hpf.  For this library, we also decided to 
test a range of doses, as it has been demonstrated that convulsant agents like 
Pentylenetetrazole work in the mM range in zebrafish
152
.  Our most pronounced hit was a 
dopamine transporter agonist called GBR13069.  In vitro and in vivo experiments with 
GBR13069 have validated it as a potent dopamine uptake inhibitor, showing increased 
motor availability in naïve mice
153
.  When screening on 3 dpf, we noticed that embryos 
treated with 100 µM had a large reduction in mCherry expression.  After a subsequent 
dose response with GBR13069 and confocal image acquisition, we noticed a reduction in 
mCherry expression specifically in the hindbrain of treated embryos (Figure 6-12).  This 
regional specificity is not surprising as it has been demonstrated that different Wnt 
ligands are also expressed regionally and loss of Wnt signaling has a compartmental 
effect on the BBB in the forebrain and ventral spinal cord
36
.  Localization of dopamine 
receptor in the zebrafish are also expressed in the hindbrain rhombomeres, areas where 
the CtAs branch off of the PHBCs
108,154
.   
 
 
Conclusion 
 
We performed small molecule screens for chemical modulators of the BBB in our 
Tg (glut1b:mCherry; fli1a:EGFP) line with the FDA and select ENZO drug libraries.  
With the FDA library we found that our main hit, statins, caused cerebral hemorrhage, 
CNS necrosis, and even death when added to embryos at 24 hpf.  We saw that when 
treated before zygotic transcription, larvae still had abnormal CNS angiogenesis but 
PHBCs underwent barriergenesis as indicated by glut1b expression.  We have previously 
seen a similar result by inhibiting VEGF signaling in BECs, confirming that CNS 
angiogenesis and barriergenesis occur via independent mechanisms.  When treated with 
statins before or after 24 hpf, larvae still had abnormal CNS angiogenesis and brain 
hemorrhage.   
 
The severity of the phenotypes correlated to the lipophilicity of each statin, 
suggesting that zebrafish can be a predictive model for statin brain penetration.  CNS 
brain hemorrhage in zebrafish after statin treatment has also been reported by other 
groups and helps validate this hit from our independent screen
150,151
.  These groups 
suggest the brain hemorrhages were due to a modification in protein prenylation.  This  
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Figure 6-11. Forskolin was a hit from both ENZO Wnt and Autophagy libraries 
10 μM Forskolin treatment at 24 hpf on Tg (glut1b:mCherry; fli1a:EGFP) embryos 
caused developmental abnormalities and seizure-like activity by 48 hpf (A).  A dose 
response with Forskolin from 10 to 1 μM shows a disruption in CNS angiogenesis (B).   
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Figure 6-12. GBR13069 dose response shows a decrease in Tg (glut1b:mCherry) in 
the hindbrain of the developing zebrafish 
GBR13069 affects the hindbrain vasculature when treated at 24 hpf.  This effect regresses 
with decreasing doses of the compound.   
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cellular process modifies many important signaling pathways such as Ras, laminin, 
Rho/Rac, and G-proteins and such signaling events have been implicated in BECs
155,156
.  
However, it is important to note that while these other groups suggest mechanisms 
through protein prenylation, the cholesterol biosynthesis pathway has other downstream 
effects such as N-linked glycosylation.  The positive control used in our small molecule 
screens, Tunicamycin, is an effective blocker of N-linked glycosylation.  Coincidentally 
when embryos are treated at 24 hpf with Tunicamycin, they also develop a phenotype 
similar to statin treated embryos.  After morpholino injections against dolk, an enzyme 
involved in N-linked glycosylation upstream of Tunicamycin, we found that there was a 
10-15% occurrence of brain hemorrhage in morphants.  While brain hemorrhage did not 
occur in all of the morphants, carriers of the p21-activated kinase 2a mutation in the 
redhead zebrafish mutant also had hemorrhage occurrence less than 100%
124
.  This 
demonstrates that phenotypes such as brain hemorrhage may not be 100% penetrant even 
with germline mutations.  While correlative, this suggests that N-linked glycosylation 
could be affected by statins during CNS angiogenesis. 
 
From the ENZO Wnt and Autophagy libraries we screened, we found that 
Forskolin was a hit common to both sets of compounds.  Enhancing cAMP levels in vitro 
enhances tight junctions through TEER and reduced permeability in BECs
157
.  cAMP has 
also been shown to elevate the induction of the tight junction Claudin5 in porcine 
BECs
158
.  However, processes that affect the initiation of barriergenesis may differ from 
signaling as it happens after the barrier is established in adults.  For example, Wnt 
signaling is important for BBB maturation but is reduced in adults
102
.  In addition to 
Forskolin from the ENZO libraries, we found that GBR13069, a dopamine uptake 
inhibitor, affects hindbrain CNS angiogenesis in the developing zebrafish.  This regional 
specificity coincides with transcript expression of dopamine receptors and hindbrain 
PHBC development
108,154
.   
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CHAPTER 7.    SUMMARY AND CONCLUSIONS 
 
 
Among the three CNS barriers, the BBB is crucial for defense against circulating 
xenobiotics and endogenous ligands that would otherwise pose a threat to the CNS
3
.  The 
BBB is a complex, physiological arrangement of brain endothelium and interacting 
astrocytic endfeet, neurons, pericytes, and microglia, all composing the NVU
23
.  Cell 
non-autonomous signals between these cells help the BBB adapt its physiological 
functions
31,33,35,36,40,41
.  However, the protection the BBB provides the CNS 
simultaneously confers drug resistance against therapeutics.  These multi-drug resistant 
mechanisms hinder the treatment of CNS diseases because efficacious drug volumes 
cannot be delivered into the brain
5
.  The paracellular barrier in between brain 
endothelium also prohibits the passive diffusion of compounds into the CNS
2
.  On the 
contrary, many CNS syndromes such as Multiple Sclerosis, Alzheimer’s and Parkinson’s 
disease present alterations in the BBB and consequently augment disease advancement
92
.  
Gaining a better understanding of healthy brain barrier signaling and physiology could 
therefore benefit the targeted delivery of CNS therapies and impede the progression of 
CNS diseases.   
 
The BBB has been studied for over a century, but only recently have molecular 
cues important for barrier development become uncovered
31,33,35,40,64
.  While informative 
to the field, these signals have been discovered with a gene candidate approach.  Finding 
novel genes that regulate the BBB in an unbiased methodology could advance the field of 
brain barrier biology.   
 
We hypothesized that zebrafish could be used a model to dissect the molecular 
mechanisms important for BBB development, maintenance, and function.  We proposed 
zebrafish could be used for unbiased chemical and genetic screening assays.  To do this, 
we initiated two specific scientific aims. The first aim was to design a transgenic BBB 
reporter line as no specific BBB reporter lines have been published to date.  For the 
second aim, we proposed to use our transgenic line for small-scale forward genetic and 
small molecule screens to discover molecular modulators of barriergenesis.   
 
Zebrafish are genetically tractable vertebrates and their quick development time 
and transparent nature makes them very amenable for developmental studies.  Zebrafish 
have been widely used for studying different biological processes and have identified 
various small molecule hits and genes involved in signaling pathways and physiological 
structures
57,109,115,146
.  The ease of mapping zebrafish genetic mutants have also made 
zebrafish an attractive model for genetic studies and the recent advancement in 
sequencing technology has promoted the appeal of using zebrafish for genetic 
screens
128,136
.  Furthermore, zebrafish have recently been used to study brain barriers, 
showing they possess a functional and homologous barrier to mammals early in 
development
61,62,66,76
.   
 
To achieve our first aim of creating a BBB transgenic reporter line, we identified 
GLUT1 as a major molecular marker for barriergenesis.  Rodent BBB studies report 
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GLUT1 as a functional indicator of barrier formation and a study simultaneously 
performed during the transgenesis of our model confirmed the specificity of Glut1 in the 
zebrafish BBB
27,28,36,64
.  To create our BBB transgenic line, we utilized the common 
Tol2kit to engineer a DNA construct with a 2.9 kb fragment of the glut1b promoter 
upstream of the mCherry transgene
84
.  After engineering our BBB DNA construct, we 
micro-injected glut1b:mCherry DNA and Tol2 transposase mRNA into single cell 
Tg(fli1a:EGFP)
 
embryos.  Observing transient expression, we identified larvae which 
expressed glut1b:mCherry specifically in fli1a:EGFP brain endothelium.  After 
achieving germline transmission of our glut1b:mCherry transgene, we saw expression co-
localized only in brain vessels and not in the periphery or circumventricular organs which 
lack barrier properties.  glut1b expression continued into adulthood and was also 
expressed in reproductive tissues.   
 
One of the ultimate goals of creating the first BBB transgenic line was to visualize 
the initial stages of barrier development as that had not be done in real time.  Two 
hypotheses exist, including that nascent CNS vessels are immature and “leaky” during 
the first stages of development or that they acquire barrier properties as soon as vessels 
migrate into the brain parenchyma
1
.  By performing live confocal microscopy, we were 
able to visualize barriergenesis occurring simultaneously with CNS angiogenesis starting 
at 30 hpf.  This was the first time the initiation of barriergenesis had been demonstrated 
in a live vertebrate.  With the creation of our Tg(glut1b:mCherry) transgenic line, we 
were therefore able to answer one of the paramount questions in brain barrier biology.    
 
We then wanted to characterize our BBB transgenic line to provide additional 
evidence that the zebrafish BBB is comparable to mammals as well as tease a part 
signaling pathways in a model system amenable to such assays.  To assess known 
molecular markers of the mammalian BBB in the zebrafish, we performed IHC on Tg 
(fli1a:EGFP) sections over the course of zebrafish development.  We found that the 
transporters Glut1 and Mdr1 as well as the tight junction protein Claudin5 are expressed 
as early as 2 dpf and continue their expression into zebrafish adulthood.  We already 
demonstrated that one of these barrier properties, glut1b, is expressed during initial CNS 
angiogenesis, but we wanted to know if these newly formed vessels were also functional.  
We performed IV injection of an Albumin tracer conjugated with an Alexa Fluorophore 
647.  Upon injection and tracer circulation, we were able to visualize that newly formed 
brain vessels were impermeable to Albumin.  While these results indicate that the 
zebrafish BBB is functional and molecularly comparable to mammals, future studies 
could examine the histological presence of other markers such as ZO-1, organic anion 
transporters, and BCRP, as well as investigate if smaller tracers are more amenable to 
leak out of nascent BECs.   
 
Zebrafish provide an excellent model organism for studying developmental 
signaling pathways and because of this, we wanted to tease a part Wnt signaling in the 
zebrafish BBB as it had been demonstrated to function in the mammalian BBB
31,36
.  
These other Wnt studies used conditional mouse knockouts which were embryonic lethal 
and therefore the BBB could not be studied past a particular time point.  Even though 
various Wnt ligands are expressed in a spatial manner throughout the brain, this is not 
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surprising as Wnt signaling is important to development of neural circuitry in 
mammals
37
.  To circumvent developmental abnormalities that could affect barriergenesis 
before it started, we crossed our BBB transgenic line to an inducible heat shock 
transgenic line to express a negative regulator of Wnt signaling, Axin-1.  By performing 
heat shock after 1 hour, we were able to demonstrate that CNS angiogenesis is ablated 
and barrier properties are ectopically expressed as they are in the mammal
36
.  It is 
satisfying that we reproduced a result seen in mammals in our BBB line, but without 
BECs it is impossible to study barrier properties.  To evade this issue, we titrated back the 
amount of Axin-1 induction to only 30 minutes of heat shock, and were able to show that 
CNS angiogenesis occurred without barriergenesis.  This suggests that even though CNS 
angiogenesis and barriergenesis occur simultaneously, they do so via different 
mechanisms.  Therefore, we proposed that barrier properties would not exist without 
angiogenesis in the brain as fundamental transplant experiments demonstrated the brain 
provides a microenvironment important for barrier function
32
.  To our surprise, after 
treating 24 hpf Tg(glut1b:mCherry;fli1a:EGFP) embryos with a potent VEGFR2 
antagonist, we saw that CNS angiogenesis did not occur but PHBCs that run alongside 
the hindbrain were still glut1b positive.  This suggested that angiogenesis is not required 
for barrier properties to form and VEGF signaling is not required for barriergenesis.   
 
We performed additional characterization studies with chemical inhibitors of Shh 
and BMP signaling as they have been studied in vascular development
33,105
.  After trying 
to chemically inhibit Shh with Cyclopamine and BMP with DMH1, we saw no effect on 
glut1b expression.  While Shh has been implicated in the mammalian BBB, this result 
suggests that these signals are not required for glut1b expression in zebrafish BECs.  
Genetic knockdown of these pathways could further and more systematically resolve 
their contribution to the zebrafish BBB.  
 
The last hypothesis we wanted to examine during the characterization of 
Tg(glut1b:mCherry) was the role of shear stress on barrier properties.  It has been 
demonstrated that the physical circulation of blood and perhaps factors within circulation, 
contribute to BBB properties
107
.  Because zebrafish can survive up to a week without a 
heartbeat, we decided to perform morpholino knockdown of tnnt2a, a gene responsible 
for cardiac contractility in the zebrafish.  Upon morpholino injection in our BBB line, 
there was no heartbeat but we were surprised to see that the glut1b signal was not 
diminished but possibly stronger in tnnt2a morphants.  The BEC lumens looked 
collapsed compared to un-injected siblings and therefore may explain any increase in 
glut1b:mCherry expression that we visualized.   
 
Upon final characterization of our BBB reporter line and completion of the first 
specific aim, we utilized the Tg (glut1b:mCherry;fli1a:EGFP) line for a F3 forward 
genetic screen and chemical screen.  For our genetic screen, adult male 
Tg(glut1b:mCherry;fli1a:EGFP)fish were treated with the carcinogenic ENU once a 
week for three weeks.  Of the original males treated, 9 males survived and were used for 
creating the subsequent F1 generation.  We were unable to perform a specific locus test 
with the nacre and roy loci to calculate an estimated ENU proficiency due to small clutch 
size and unwillingness of the F0 males to breed with Casper females.  However, after fish 
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recovered their first treatment, we tested the efficiency of ENU treatment by crossing 
treated males to untreated TL females.  We saw that after only one round of treatment, 
the ENU concentration was highly effective due to a complete elimination of fli1a:EGFP 
expression in progeny from the founder male.  We generated 625 F1 males and 210 F2 
families.  To date, of these 210 families 114 families survived and 68 families have been 
screened.  From these 68 families, 4 BBB mutants have been identified, confirmed, and 
out-crossed to polymorphic strains for genetic studies.  In families 40, 44, and 196, 
mutants were found that had little to no CNS angiogenesis but normal peripheral 
angiogenesis.  Family 22 harbored our most interesting mutant, line 22.6, whereby there 
was still a degree of CNS angiogenesis that took place but a major reduction in 
glut1b:mCherry expression.  These 4 lines represent the first zebrafish BBB mutants 
produced from a forward genetic screen.   
 
We wanted to follow-up and clone the 22.6 mutant to identify a potential novel 
regulator of barriergenesis.  Positional cloning is commonly performed in the zebrafish 
with bulk segregant analysis PCR
129
.  While this method has cloned zebrafish mutants, it 
is not fully guaranteed for every mutant identified in a genetic screen
134
.  To increase our 
chances of cloning 22.6, we simultaneously performed exome sequencing on pools from 
22.6 mutant and wild-type sibling genomic DNA.  After bioinformatics analysis was 
performed in the Hartwell Center at St. Jude Children’s Research Hospital, two candidate 
mutations were identified.  Both candidate alleles were PCR amplified and sequenced 
from the original individual wild-type and 22.6 mutant samples.  We confirmed that 
gpr124 was the mutated allele in the 22.6 line, whereby a G to A point mutation causes a 
premature stop codon at 981 amino acids in the protein sequence.  The premature stop 
codon was also stronger evidence for the mutation of gpr124.  Furthermore, sequencing 
revealed that the candidate adra2b mutation was a polymorphism among wild-type 
siblings.  While the first BBB mutant we cloned was in a gene known to be important for 
mammalian barriergenesis, this result confirmed our whole screening strategy and that we 
could faithfully identify BBB mutants
35,126
.   
 
We next wanted to characterize the gpr124
 -/- 
mutant to look for similarities and 
potential differences between our fish line and the mammalian knockout models.  
Gpr124
-/-
 knockout mice present brain hemorrhages and die embryonically
35,126
.  While 
we did not identify any brain hemorrhages in gpr124
-/-
 after it was out-crossed to TL, we 
did visualize that the gpr124
-/-
 barrier was “leakier” compared to wild-type siblings after 
IV injection with 3,000 Da Cascade Blue and 10 kDa Rhodamine tracers.  Mutants also 
appeared leakier when bathed in 332 Da Fluorescein dye.  Because protein albumin is 
much larger than these tracers, this could suggest a difference in size-selectivity upon 
ablation of gpr124 in zebrafish compared to mammals.  We also looked at Claudin5 
expression in gpr124
-/-
 to identify if that was the cause for tracer leakage.  Claudin5
-/-
 
mice also do not present brain hemorrhage but do show a size-selective loosening of the 
barrier like our gpr124
-/ 
when injected with tracer dyes
22
.  It is hypothesized that the 
absence of brain hemorrhage in the zebrafish gpr124
-/-
 may also be due to compensation 
from another zebrafish g-coupled protein receptor paralog resulting from the zebrafish 
genome duplication event
46
.  Ultimately, identification of the first zebrafish gpr124
-/-
 
mutant could lead to small molecule screens or future protein studies that identify the 
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ligand for this orphan receptor.  Identification of the gpr124 ligand could also prove 
useful as a therapeutic target in CNS drug delivery as many therapeutics target g-coupled 
proteins
139
.  RNA-seq experiments with gpr124
-/- 
and wild-type siblings may elucidate 
additional signals important for barriergenesis.   
 
While we spawned the various generations for our F3 forward genetic screen, we 
simultaneously performed small molecule screens to identify chemical modulators of the 
BBB.  To date, we have screened the FDA and ENZO Wnt, Autophagy, and 
Neurotransmitter libraries.  From the 884 compounds in the FDA library, we identified 
our most conspicuous hit to be a class of compounds called statins.  We found that 
depending on the statin, zebrafish treated at 24 hpf developed CNS necrosis, brain 
hemorrhage and even death by 48 hpf and had reduced CNS angiogenesis.  Statins are 
known reducers of cholesterol biosynthesis, but recent zebrafish studies have shown that 
statins induce brain hemorrhage in zebrafish via mechanisms independent of cholesterol 
inhibition
150,151
.  While our finding was not unique, our work from the FDA screen was 
confirmed by other groups.  Furthermore, after performing several dose responses with 
the range of statins available, we found that based on the lipophilicity of the statin, 
zebrafish were a predictive indicator of BBB statin penetration.  With a developmental 
treatment time course, we were also able to establish that statin treatment before zygotic 
transcription or later at 48 hpf still caused brain hemorrhage and reduced CNS 
angiogenesis in the developing zebrafish.  Brain hemorrhages were no longer seen in fish 
treated at 5dpf, suggesting a developmental effect of statin treatment during 
barriergenesis.  This raises concern for pregnant women with hypercholesterolemia, but 
the safety of statin treatment during pregnancy is dubious due to conflicting evidence and 
high treatment regimens in animal studies versus what is observed in humans 
159
.  
Furthermore, signals important for barrier maturation may deviate from signals in 
differentiated BECs
102
.   
 
While mechanisms have been suggested by other groups, we suggested that 
modification of N-linked glycosylation could be why statins cause brain hemorrhage.  
We suggest this because after treatment with Tunicamycin, a potent inhibitor of N-linked 
glycosylation, zebrafish have reduced CNS angiogenesis and develop brain hemorrhages.  
Also, upon morpholino knockdown of dolk, the enzyme upstream Tunicamycin’s target, 
we find that CNS angiogenesis is disrupted and a percentage of morphants develop brain 
hemorrhage.  Even though we only saw at most 15% of morphants with brain 
hemorrhage, this could be because dolk is maternally derived and the morpholino diffuses 
in the animal over time.  Future studies using techniques like CRISPR knockout of the 
dolk gene may be able to produce a more penetrant brain hemorrhage phenotype and 
study the consequence of true dolk knockout effects on the BBB.  It would also be 
interesting to perform protein or RNA-seq studies on Tunicamycin-treated embryos to 
see if there are particular N-linked glycosylated proteins in the BBB that are affected 
after Tunicamycin treatment and cause the subsequent brain hemorrhage phenotype.   
 
We identified two other chemical hits from the ENZO library screens, Forskolin 
and GBR13069.  Forskolin a known elevator of cAMP signaling, has been indicated in 
enhancing TEER and reducing tight junction permeability
157
.  Upon treatment with 
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Forskolin, zebrafish had increased motor activity and a marked reduction in CNS 
angiogenesis.  GBR13069 is a dopamine uptake inhibitor which has shown increased 
motor activity in mice
153
.  After GBR13069 treatment, zebrafish had a discernible 
reduction in the Tg(glut1b:mCherry) signal.  This reduction seemed to be hindbrain 
specific which is congruent with dopamine receptor expression in the zebrafish larvae
154
.  
Both of these compounds also remained effective with individual dose responses.  These 
hits confirm the presence of cAMP signaling in the BBB as well as the first report on 
how neurons may specifically regulate barriergenesis.   
 
The development of Tg(glut1b:mCherry) helped elucidate questions about 
barriergenesis in a developing vertebrate that until now have not been possible.  Glut1 is 
only one marker for the BBB and therefore it could be suggested that Glut1 cannot be the 
solitary indicator of barrier properties.  However, this marker is supported by studies 
performed in mammals that use Glut1 as a sole indicator of barrier integrity
27,35
.  
Additional zebrafish BBB transgenic lines should be generated to see if the results found 
from our studies with glut1b hold true with other markers.  We demonstrate that our BBB 
line was useful for studying the onset of barriergenesis, pathways that modulate this 
process, the discovery of BBB mutants, and identification of compounds that may 
uncover novel regulators of barriergenesis.  Therefore, the work in this dissertation will 
guide the understanding of the molecular mechanisms that help develop and maintain a 
healthy BBB.  Recognizing these process prove to be crucial for furthering the 
development of CNS therapies, targets for better CNS drug penetration, and the 
prevention of CNS disease progression. 
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